|
US5800815A
(en)
*
|
1903-05-05 |
1998-09-01 |
Cytel Corporation |
Antibodies to P-selectin and their uses
|
|
US5851526A
(en)
*
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
|
US5449760A
(en)
*
|
1987-12-31 |
1995-09-12 |
Tanox Biosystems, Inc. |
Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US7247453B1
(en)
*
|
1988-12-30 |
2007-07-24 |
Oklahoma Medical Research Foundation |
Calcium binding recombinant antibody against protein C
|
|
DE3900534A1
(de)
*
|
1989-01-10 |
1990-07-12 |
Boehringer Mannheim Gmbh |
Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
GR1001050B
(el)
*
|
1990-01-09 |
1993-04-28 |
Protein Design Labs Inc |
Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
|
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
|
GB9020282D0
(en)
|
1990-09-17 |
1990-10-31 |
Gorman Scott D |
Altered antibodies and their preparation
|
|
US5858725A
(en)
*
|
1990-10-10 |
1999-01-12 |
Glaxo Wellcome Inc. |
Preparation of chimaeric antibodies using the recombinant PCR strategy
|
|
US5994510A
(en)
*
|
1990-12-21 |
1999-11-30 |
Celltech Therapeutics Limited |
Recombinant antibodies specific for TNFα
|
|
ES2204890T3
(es)
*
|
1991-03-06 |
2004-05-01 |
Merck Patent Gmbh |
Anticuerpos monoclonales humanizados.
|
|
IL101147A
(en)
*
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Change of direction of cellular immunity by chimera receptors
|
|
DK0578774T3
(da)
*
|
1991-04-05 |
1999-04-26 |
Univ Washington |
Monoklonale antistoffer mod stamcellefaktor-receptorer
|
|
HU218140B
(hu)
*
|
1991-04-25 |
2000-06-28 |
Chugai Seiyaku Kabushiki Kaisha |
Humán interleukin-6-receptorral szembeni átalakított humán antitest
|
|
DE69233482T2
(de)
*
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
DE69233254T2
(de)
*
|
1991-06-14 |
2004-09-16 |
Genentech, Inc., South San Francisco |
Humanisierter Heregulin Antikörper
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9115010D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Wellcome Found |
Antibody
|
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
|
US5709860A
(en)
*
|
1991-07-25 |
1998-01-20 |
Idec Pharmaceuticals Corporation |
Induction of cytotoxic T-lymphocyte responses
|
|
WO1993001831A1
(en)
*
|
1991-07-25 |
1993-02-04 |
Idec Pharmaceuticals Corporation |
Induction of cytotoxic t-lymphocyte responses
|
|
MX9204374A
(es)
*
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
US6329509B1
(en)
*
|
1991-08-14 |
2001-12-11 |
Genentech, Inc. |
Anti-IgE antibodies
|
|
US6685939B2
(en)
|
1991-08-14 |
2004-02-03 |
Genentech, Inc. |
Method of preventing the onset of allergic disorders
|
|
PT528767E
(pt)
*
|
1991-08-21 |
2000-06-30 |
Novartis Ag |
Derivados de anticorpos
|
|
GB9120467D0
(en)
*
|
1991-09-26 |
1991-11-06 |
Celltech Ltd |
Anti-hmfg antibodies and process for their production
|
|
JP3024311B2
(ja)
*
|
1991-10-03 |
2000-03-21 |
味の素株式会社 |
Ｉｌ−２受容体重鎖に結合するポリペプチド
|
|
US5474771A
(en)
*
|
1991-11-15 |
1995-12-12 |
The Trustees Of Columbia University In The City Of New York |
Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
|
|
US7070777B1
(en)
|
1991-11-15 |
2006-07-04 |
The Trustees Of Columbia University In The City Of New York |
Method for inhibiting inflammation with an antibody that binds the 5C8 protein
|
|
US5817310A
(en)
*
|
1991-12-02 |
1998-10-06 |
Cor Therapeutics, Inc. |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
|
|
JPH05244982A
(ja)
*
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化ｂ−ｂ１０
|
|
US5766886A
(en)
*
|
1991-12-13 |
1998-06-16 |
Xoma Corporation |
Modified antibody variable domains
|
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
US5777085A
(en)
*
|
1991-12-20 |
1998-07-07 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with GPIIB/IIIA
|
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
|
DE69334351D1
(de)
*
|
1992-02-06 |
2011-05-12 |
Novartis Vaccines & Diagnostic |
Biosynthetisches Bindeprotein für Tumormarker
|
|
GB9203459D0
(en)
*
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5387676A
(en)
*
|
1992-03-11 |
1995-02-07 |
Ciba Corning Diagnostics Corp. |
MN gene and protein
|
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
|
US6033667A
(en)
*
|
1992-05-05 |
2000-03-07 |
Cytel Corporation |
Method for detecting the presence of P-selectin
|
|
US5874082A
(en)
*
|
1992-07-09 |
1999-02-23 |
Chiron Corporation |
Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
|
|
US5397703A
(en)
*
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
|
US5639641A
(en)
*
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5958708A
(en)
*
|
1992-09-25 |
1999-09-28 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
|
US6066718A
(en)
*
|
1992-09-25 |
2000-05-23 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
|
GB9223377D0
(en)
*
|
1992-11-04 |
1992-12-23 |
Medarex Inc |
Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
|
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5648267A
(en)
*
|
1992-11-13 |
1997-07-15 |
Idec Pharmaceuticals Corporation |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
|
|
DE69303494T2
(de)
*
|
1992-11-13 |
1997-01-16 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
ES2088838T3
(es)
*
|
1992-11-13 |
2004-01-01 |
Idec Pharmaceuticals Corporation |
Secuencias kozak de consenso totalmente alteradas destinadas a la expresion en los mamiferos.
|
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
|
US5804187A
(en)
*
|
1992-11-16 |
1998-09-08 |
Cancer Research Fund Of Contra Costa |
Modified antibodies with human milk fat globule specificity
|
|
JPH08507680A
(ja)
|
1993-01-12 |
1996-08-20 |
バイオジェン インコーポレイテッド |
組換え抗ｖｌａ４抗体分子
|
|
US5730979A
(en)
*
|
1993-03-05 |
1998-03-24 |
Universite Catholique Delouvain |
LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
|
|
US5951983A
(en)
*
|
1993-03-05 |
1999-09-14 |
Universite Catholique De Louvain |
Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
|
|
US5817311A
(en)
*
|
1993-03-05 |
1998-10-06 |
Universite Catholique De Louvain |
Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
|
|
WO1994025067A1
(en)
*
|
1993-05-04 |
1994-11-10 |
Cytel Corporation |
Antibodies to p-selectin and their uses
|
|
US5820858A
(en)
*
|
1993-05-28 |
1998-10-13 |
The Scripps Research Institute |
Methods and compositions for inhibiting CD14 mediated cell activation
|
|
ZA943778B
(en)
*
|
1993-05-31 |
1995-02-21 |
Chugai Seiyaku Kagushiki Kaish |
Reshaped human antibody to human interleukin-6
|
|
US6180377B1
(en)
*
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
US5914110A
(en)
*
|
1993-09-07 |
1999-06-22 |
Smithkline Beecham Corporation |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
US5928904A
(en)
*
|
1993-09-07 |
1999-07-27 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
SK285556B6
(sk)
*
|
1993-09-07 |
2007-03-01 |
Smithkline Beecham Corporation |
Fúzny proteín so špecifickou väzbou na ľudský IL-4, molekula nukleovej kyseliny, monoklonálne protilátky, farmaceutická kompozícia a použitie
|
|
AU7949394A
(en)
|
1993-11-19 |
1995-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human medulloblastomatous cell
|
|
WO1995015181A1
(en)
*
|
1993-11-30 |
1995-06-08 |
Protein Design Labs, Inc. |
Reperfusion therapy using antibodies to l-selectin
|
|
GB9325182D0
(en)
*
|
1993-12-08 |
1994-02-09 |
T Cell Sciences Inc |
Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
|
|
CN1211123C
(zh)
*
|
1994-01-25 |
2005-07-20 |
雅典娜神经科学公司 |
抗白细胞粘附分子vla－4的人源化抗体
|
|
US7435802B2
(en)
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
|
US5840299A
(en)
*
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
|
ATE240395T1
(de)
|
1994-03-29 |
2003-05-15 |
Celltech Therapeutics Ltd |
Antikörper gegen e-selektin
|
|
US5635597A
(en)
*
|
1994-05-27 |
1997-06-03 |
Affymax Technologies, N.V. |
Peptides that bind IL-2 receptors
|
|
US5622701A
(en)
*
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
|
GB9412230D0
(en)
|
1994-06-17 |
1994-08-10 |
Celltech Ltd |
Interleukin-5 specific recombiant antibodies
|
|
USRE39548E1
(en)
*
|
1994-06-17 |
2007-04-03 |
Celltech R&D Limited |
Interleukin-5 specific recombinant antibodies
|
|
US6048972A
(en)
*
|
1994-07-13 |
2000-04-11 |
Chugai Pharmaceutical Co., Ltd. |
Recombinant materials for producing humanized anti-IL-8 antibodies
|
|
DE4425115A1
(de)
*
|
1994-07-15 |
1996-01-18 |
Boehringer Mannheim Gmbh |
Verfahren zur Modifizierung der Stabilität von Antikörpern
|
|
EP0696455A1
(en)
*
|
1994-08-11 |
1996-02-14 |
Cellena (Cell Engineering) A.G. |
Transferrin compositions to alleviate the side effects of cytotoxic drugs
|
|
US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
|
US5707621A
(en)
*
|
1994-08-31 |
1998-01-13 |
Chugai Pharmaceutical Co., Ltd. |
Supression of nephritis-induced protein excretion by anti-IL-8
|
|
US6309636B1
(en)
*
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
|
US5683892A
(en)
*
|
1994-12-23 |
1997-11-04 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
|
|
AU6171196A
(en)
*
|
1995-06-07 |
1996-12-30 |
Sloan-Kettering Institute For Cancer Research |
Therapeutic uses of ta99
|
|
US7153508B2
(en)
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
|
US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
|
US7175847B1
(en)
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
|
US6001358A
(en)
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
|
US6440418B1
(en)
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
|
GB9600660D0
(en)
|
1996-01-12 |
1996-03-13 |
Ciba Geigy Ag |
Protein
|
|
WO1997033617A1
(en)
*
|
1996-03-13 |
1997-09-18 |
Protein Design Labs, Inc. |
Fas ligand fusion proteins and their uses
|
|
US5882644A
(en)
*
|
1996-03-22 |
1999-03-16 |
Protein Design Labs, Inc. |
Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
|
|
US6713305B1
(en)
|
1996-04-29 |
2004-03-30 |
Novartis Ag |
Metastasis-associated antigen and antibodies thereto
|
|
EP1378525A3
(en)
|
1996-06-07 |
2004-01-14 |
Neorx Corporation |
Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
|
|
US6534311B2
(en)
|
1996-07-24 |
2003-03-18 |
Novartis Ag |
Drosophila melanogaster p70S6 kinase
|
|
US6833255B1
(en)
|
1996-07-24 |
2004-12-21 |
Novartis, Ag |
Drosophila melanogaster p70 S6 kinase
|
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
|
AU725329B2
(en)
*
|
1996-09-02 |
2000-10-12 |
Ko Okumura |
Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
|
|
US6013256A
(en)
*
|
1996-09-24 |
2000-01-11 |
Protein Design Labs, Inc. |
Method of preventing acute rejection following solid organ transplantation
|
|
CN100335501C
(zh)
|
1996-09-26 |
2007-09-05 |
中外制药株式会社 |
抗人副甲状腺激素相关蛋白的抗体
|
|
UA76934C2
(en)
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
|
US7883872B2
(en)
|
1996-10-10 |
2011-02-08 |
Dyadic International (Usa), Inc. |
Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
|
|
WO2000020555A2
(en)
|
1998-10-06 |
2000-04-13 |
Aarl Inc |
Transformation system in the field of filamentous fungal hosts: in chrysosporium
|
|
US20020160005A1
(en)
|
1996-11-15 |
2002-10-31 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic urmec syndrome
|
|
US7910096B2
(en)
|
1996-11-15 |
2011-03-22 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic uremic syndrome
|
|
EP0946725B1
(en)
|
1996-12-23 |
2011-01-26 |
Immunex Corporation |
Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
|
|
US6262238B1
(en)
*
|
1997-01-14 |
2001-07-17 |
Roche Diagnostic, Gmbh |
Process for modifying the stability of antibodies
|
|
US6596850B1
(en)
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
|
US6590079B2
(en)
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
|
US20030109680A1
(en)
|
2001-11-21 |
2003-06-12 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US20060235209A9
(en)
|
1997-03-10 |
2006-10-19 |
Jin-An Jiao |
Use of anti-tissue factor antibodies for treating thromboses
|
|
US5986065A
(en)
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US7749498B2
(en)
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
IL123756A0
(en)
*
|
1997-03-21 |
1998-10-30 |
Sankyo Co |
Humanized anti-human FAS antibody
|
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
TR199903123T2
(xx)
|
1997-04-07 |
2000-05-22 |
Genentech, Inc. |
Anti-Vegf antikorlar�.
|
|
IL132896A0
(en)
|
1997-05-15 |
2001-03-19 |
Chugai Pharmaceutical Co Ltd |
Cachexia remedy
|
|
JP2002512624A
(ja)
*
|
1997-05-21 |
2002-04-23 |
バイオベーション リミテッド |
非免疫原性タンパク質の製造方法
|
|
US7507705B2
(en)
|
1997-10-02 |
2009-03-24 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
|
|
IL135221A0
(en)
*
|
1997-10-03 |
2001-05-20 |
Chugai Pharmaceutical Co Ltd |
Natural humanized antibody and methods for the preparation thereof
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
EP1745799B1
(en)
|
1998-03-04 |
2015-09-02 |
The Trustees of The University of Pennsylvania |
Compositions and methods of treating tumors
|
|
JP3998419B2
(ja)
|
1998-04-03 |
2007-10-24 |
中外製薬株式会社 |
ヒト組織因子（ｔｆ）に対するヒト型化抗体およびヒト型化抗体の作製方法
|
|
KR101023367B1
(ko)
|
1998-08-11 |
2011-03-18 |
바이오겐 아이덱 인크. |
Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
|
|
JP4689781B2
(ja)
*
|
1998-09-03 |
2011-05-25 |
独立行政法人科学技術振興機構 |
アミノ酸輸送蛋白及びその遺伝子
|
|
NZ511062A
(en)
|
1998-09-14 |
2003-04-29 |
Univ Texas |
Antagonists of alpha4 containing integrins, which inhibit the biological effects of adhesion interaction in myeloma bone disease
|
|
EP1939215A1
(en)
|
1998-10-22 |
2008-07-02 |
The University of Montana |
Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
|
|
EP1949912A3
(en)
|
1998-11-09 |
2008-08-13 |
Biogen Idec, Inc. |
Treatment of chronic lymphcytic leukemia (CLL) using chimeric anti-CD20 antibody
|
|
GB9825632D0
(en)
|
1998-11-23 |
1999-01-13 |
Novartis Ag |
Organic compounds
|
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
|
IL139321A0
(en)
|
1999-03-03 |
2001-11-25 |
Biogen Inc |
Methods and compositions for modulating lipid metabolism
|
|
GB9906380D0
(en)
*
|
1999-03-19 |
1999-05-12 |
Melvin William T |
Monoclonal antibodies specific for cypibi
|
|
CN1332714C
(zh)
|
1999-04-22 |
2007-08-22 |
比奥根艾迪克Ma公司 |
整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物组合物中的用途
|
|
IT1306704B1
(it)
*
|
1999-05-26 |
2001-10-02 |
Sirs Societa Italiana Per La R |
Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
|
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
SI2314315T1
(sl)
|
1999-06-01 |
2015-04-30 |
Biogen Idec Ma Inc. |
Blokirno monoklonsko protitelo proti humani alfa1 i-domeni vla-1 in njegova uporaba za zdravljenje vnetnih obolenj
|
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
|
US6531580B1
(en)
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
|
TWI255718B
(en)
|
1999-07-02 |
2006-06-01 |
Chugai Pharmaceutical Co Ltd |
Ameliorative agent for low vasopressin concentration
|
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
|
JP4689124B2
(ja)
*
|
1999-09-30 |
2011-05-25 |
協和発酵キリン株式会社 |
ガングリオシドｇｄ３に対するヒト型相補性決定領域移植抗体およびガングリオシドｇｄ３に対する抗体の誘導体
|
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
|
PT1234031T
(pt)
|
1999-11-30 |
2017-06-26 |
Mayo Foundation |
B7-h1, uma nova molécula imunoregulatória
|
|
ATE447969T1
(de)
|
1999-12-16 |
2009-11-15 |
Biogen Idec Inc |
Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
|
|
WO2001055217A1
(en)
|
2000-01-27 |
2001-08-02 |
Medimmune, Inc. |
Ultra high affinity neutralizing antibodies
|
|
MXPA02007449A
(es)
*
|
2000-02-03 |
2003-04-14 |
Millennium Pharm Inc |
Anticuerpos anti-ccr2 humanizados y metodos para el uso de los mismos.
|
|
AU3495301A
(en)
|
2000-02-11 |
2001-08-20 |
Biogen Inc |
Heterologous polypeptide of the tnf family
|
|
CN101670105B
(zh)
|
2000-02-24 |
2014-08-06 |
华盛顿大学 |
螯合淀粉样蛋白β肽的人源化抗体
|
|
DK1259547T3
(da)
|
2000-03-01 |
2012-10-15 |
Medimmune Inc |
Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
|
|
WO2001070266A2
(en)
|
2000-03-17 |
2001-09-27 |
Millennium Pharmaceuticals, Inc. |
Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
|
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
WO2001082968A1
(fr)
|
2000-04-28 |
2001-11-08 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibiteurs de proliferation cellulaire
|
|
ATE412185T1
(de)
|
2000-04-29 |
2008-11-15 |
Univ Iowa Res Found |
Diagnostika und therapeutika für makula degeneration erkrankungen
|
|
US7279160B2
(en)
|
2000-05-02 |
2007-10-09 |
The Uab Research Foundation |
Combinations of DR5 antibodies and other therapeutic agents
|
|
TWI318983B
(en)
|
2000-05-02 |
2010-01-01 |
Uab Research Foundation |
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
|
|
US7476383B2
(en)
|
2000-05-02 |
2009-01-13 |
The Uab Research Foundation |
Antibody selective for DR4 and uses thereof
|
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
|
US7288252B2
(en)
|
2000-10-02 |
2007-10-30 |
Novartis Vaccines And Diagnostics, Inc. |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
|
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
AU2002315271B2
(en)
*
|
2001-04-06 |
2006-08-03 |
University Of Bristol |
Use of CD25 binding molecules in steroid-resistant patients
|
|
PL367324A1
(en)
|
2001-04-13 |
2005-02-21 |
Biogen, Inc. |
Antibodies to vla-1
|
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
|
EA200301169A1
(ru)
*
|
2001-05-18 |
2004-06-24 |
Бёрингер Ингельхайм Интернациональ Гмбх |
АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ CD44v6
|
|
US7541443B2
(en)
*
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
|
AU2002314495A1
(en)
|
2001-06-20 |
2003-01-02 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
US20030013081A1
(en)
|
2001-06-26 |
2003-01-16 |
Olson William C. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
|
JP4675512B2
(ja)
*
|
2001-07-10 |
2011-04-27 |
三井化学株式会社 |
熱殺菌方法
|
|
JP2005522192A
(ja)
|
2001-07-19 |
2005-07-28 |
パーラン セラピューティクス， インコーポレイテッド |
マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
|
|
EP1420032B2
(en)
†
|
2001-08-03 |
2015-12-16 |
Medical & Biological Laboratories Co., Ltd. |
Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
|
|
EP1944040B1
(en)
|
2001-08-17 |
2012-08-01 |
Washington University |
Assay method for Alzheimer's disease
|
|
EP3187592B1
(en)
|
2001-09-20 |
2018-12-12 |
Immunex Corporation |
Selection of cells expressing heteromeric polypeptides
|
|
AU2002332290B2
(en)
|
2001-09-25 |
2007-11-08 |
Astellas Pharma Inc. |
Recombinant anti-osteopontin antibody and use thereof
|
|
GB0124317D0
(en)
|
2001-10-10 |
2001-11-28 |
Celltech R&D Ltd |
Biological products
|
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
|
AU2002351957B2
(en)
*
|
2001-11-12 |
2009-09-03 |
Merck Patent Gmbh |
Modified anti-TNF alpha antibody
|
|
EP1944043A1
(en)
|
2001-11-21 |
2008-07-16 |
The Trustees of the University of Pennsylvania |
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
|
|
EP2286841A1
(en)
|
2001-11-21 |
2011-02-23 |
The Trustees of The University of Pennsylvania |
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
|
|
AR037456A1
(es)
|
2001-11-30 |
2004-11-10 |
Biogen Inc |
Anticuerpos contra proteinas quimiotacticas monocitarias
|
|
US7393648B2
(en)
|
2001-12-03 |
2008-07-01 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
|
SI1461428T1
(sl)
|
2001-12-03 |
2012-07-31 |
Alexion Pharma Inc |
Postopek za proizvodnjo hibridnih protiteles
|
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
|
WO2003068821A2
(en)
*
|
2002-02-14 |
2003-08-21 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
|
CA2476901C
(en)
*
|
2002-02-22 |
2012-10-09 |
Progenics Pharmaceuticals, Inc. |
Anti-ccr5 antibody
|
|
SI1485127T1
(sl)
|
2002-02-25 |
2011-09-30 |
Elan Pharm Inc |
Dajanje aktivne snovi za zdravljenje vnetja
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
ES2389037T3
(es)
|
2002-03-13 |
2012-10-22 |
Biogen Idec Ma Inc. |
Anticuerpos anti-alpha V beta 6
|
|
AU2003225900A1
(en)
|
2002-03-20 |
2003-10-08 |
Pharmacia Corporation |
Antibody disulfide isomers, use thereof, and methods of analyzing same
|
|
CA2480059C
(en)
*
|
2002-03-22 |
2015-11-24 |
Amrad Operations Pty. Ltd. |
Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
|
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
US7202067B2
(en)
|
2002-05-14 |
2007-04-10 |
Martek Biosciences Corporation |
Carotene synthase gene and uses therefor
|
|
JP4418745B2
(ja)
|
2002-05-28 |
2010-02-24 |
ユセベ ファルマ ソシエテ アノニム |
抗体ｐｅｇ位置異性体、それを含む組成物及びその使用
|
|
AU2003232456B2
(en)
*
|
2002-05-30 |
2009-06-04 |
Macrogenics, Inc. |
CD16A binding proteins and use for the treatment of immune disorders
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
GB0213745D0
(en)
|
2002-06-14 |
2002-07-24 |
Univ Edinburgh |
Enzyme
|
|
US7544483B2
(en)
|
2002-06-14 |
2009-06-09 |
Monier Tadros |
Method for the production of protamine
|
|
AU2002368055B2
(en)
|
2002-06-28 |
2008-09-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
|
|
US9535076B2
(en)
|
2002-09-12 |
2017-01-03 |
The Regents Of The University Of California |
Methods and compositions for eliciting an amyloid-selective immune response
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
GB0228832D0
(en)
|
2002-12-10 |
2003-01-15 |
Novartis Ag |
Organic compound
|
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
|
NZ540555A
(en)
*
|
2002-11-15 |
2008-04-30 |
Genmab As |
Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
|
|
JP2007531505A
(ja)
|
2002-11-27 |
2007-11-08 |
ミネルバ バイオオテクノロジーズ コーポレーション |
癌（ｍｕｃ１）の診断および治療のための技術および組成物
|
|
HUE035898T2
(en)
|
2002-12-16 |
2018-05-28 |
Genentech Inc |
Immunoglobulin variants and their applications
|
|
WO2004065417A2
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
|
EP1592387A4
(en)
|
2003-01-24 |
2009-05-06 |
Elan Pharm Inc |
COMPOSITION AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
|
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
US7321065B2
(en)
|
2003-04-18 |
2008-01-22 |
The Regents Of The University Of California |
Thyronamine derivatives and analogs and methods of use thereof
|
|
SG173919A1
(en)
|
2003-04-23 |
2011-09-29 |
Medarex Inc |
Compositions and methods for the therapy of inflammatory bowel disease
|
|
AU2004233346B2
(en)
*
|
2003-04-23 |
2008-03-06 |
Medarex, Inc. |
Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
|
|
SI1633189T1
(sl)
|
2003-05-19 |
2017-12-29 |
Prothena Biosciences Limited |
Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc
|
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
|
WO2005003175A2
(en)
|
2003-06-13 |
2005-01-13 |
Biogen Idec Ma Inc. |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
|
US8153410B2
(en)
|
2003-07-07 |
2012-04-10 |
Fox Chase Cancer Center |
Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
|
|
US20060162014A1
(en)
|
2003-07-07 |
2006-07-20 |
Jaffe Eileen K |
Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
|
|
DK2784084T4
(da)
|
2003-07-08 |
2024-01-08 |
Novartis Pharma Ag |
Antagonist-antistoffer mod IL-17A/F heterologe polypeptider
|
|
CN101124240B
(zh)
|
2003-07-18 |
2013-12-18 |
安姆根有限公司 |
肝细胞生长因子的特异性结合物
|
|
US7834155B2
(en)
|
2003-07-21 |
2010-11-16 |
Immunogen Inc. |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
|
GB0321997D0
(en)
|
2003-09-19 |
2003-10-22 |
Novartis Ag |
Organic compound
|
|
AU2004287722A1
(en)
*
|
2003-11-11 |
2005-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized anti-CD47 antibody
|
|
JP2007514413A
(ja)
|
2003-11-12 |
2007-06-07 |
プロジェニクス・ファーマスーティカルズ・インコーポレイテッド |
Ｃ型肝炎ウイルス糖タンパク質をコードする新規配列
|
|
US7700737B2
(en)
|
2003-12-05 |
2010-04-20 |
Multimmune Gmbh |
Therapeutic and diagnostic anti-Hsp70 antibodies
|
|
JP2008504218A
(ja)
|
2003-12-08 |
2008-02-14 |
モルフォテック、インク． |
Ｐｍｓ２と特異的に結合する抗体
|
|
EP2241331A3
(en)
|
2003-12-15 |
2011-03-09 |
Alexion Pharmaceuticals, Inc. |
Novel anti-DC-SIGN antibodies
|
|
ITRM20030601A1
(it)
*
|
2003-12-24 |
2005-06-25 |
Lay Line Genomics Spa |
Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
|
|
AU2005205533B2
(en)
|
2004-01-07 |
2012-03-22 |
Novartis Vaccines And Diagnostics, Inc. |
M-CSF-specific monoclonal antibody and uses thereof
|
|
US20070280950A1
(en)
|
2004-01-19 |
2007-12-06 |
Medical And Biological Laboratories Co., Ltd. |
Inflammatory Cytokine Inhibitors
|
|
WO2005081783A2
(en)
|
2004-01-30 |
2005-09-09 |
Dana Farber Cancer Institute |
Method for determination and quantification of radiation or genotoxin exposure
|
|
WO2005077417A1
(en)
|
2004-02-10 |
2005-08-25 |
The Regents Of The University Of Colorado |
Inhibition of factor b, the alternative complement pathway and methods related thereto
|
|
AU2005214331B2
(en)
|
2004-02-12 |
2011-09-15 |
Eisai, Inc. |
Monoclonal antibodies that specifically bind to folate receptor alpha
|
|
TWI359026B
(en)
|
2004-02-12 |
2012-03-01 |
Sankyo Co |
Pharmaceutical composition for the osteoclast rela
|
|
JP4824547B2
(ja)
|
2004-02-20 |
2011-11-30 |
インテレクト ニュウロサイエンシス，インク． |
モノクローナル抗体およびその利用
|
|
EP2287194B1
(en)
|
2004-03-12 |
2016-10-26 |
Vasgene Therapeutics, Inc. |
Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
|
|
US20050260679A1
(en)
|
2004-03-19 |
2005-11-24 |
Sirid-Aimee Kellerman |
Reducing the risk of human anti-human antibodies through V gene manipulation
|
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
|
ES2411965T3
(es)
|
2004-04-02 |
2013-07-09 |
The Regents Of The University Of California |
Métodos y composiciones para tratar y prevenir enfermedad asociada con integrina alfa V beta 5
|
|
CA2568201C
(en)
|
2004-05-24 |
2013-07-30 |
Universitat Zu Koln |
Identification of ergothioneine transporter and therapeutic uses thereof
|
|
EP1602926A1
(en)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Novel means and methods for the treatment of hearing loss and phantom hearing
|
|
CN101001878B
(zh)
|
2004-06-21 |
2012-09-26 |
米德列斯公司 |
干扰素α受体1抗体及其用途
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
EA014226B1
(ru)
|
2004-07-26 |
2010-10-29 |
Байоджен Айдек Ма Инк. |
Антитела к cd154, их фрагменты и способы применения антител и фрагментов
|
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
|
MX2007001679A
(es)
|
2004-08-09 |
2007-05-23 |
Elan Pharm Inc |
Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
|
|
CA2478458A1
(en)
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
FI20041204A0
(fi)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
|
|
ATE497508T1
(de)
|
2004-10-01 |
2011-02-15 |
Max Planck Gesellschaft |
Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
|
|
EP1810026B1
(en)
|
2004-10-06 |
2018-04-18 |
Mayo Foundation For Medical Education And Research |
B7-h1 and pd-1 in treatment of renal cell carcinoma
|
|
MX2007004437A
(es)
|
2004-10-22 |
2007-06-20 |
Amgen Inc |
Metodos para el repliegue de anticuerpos recombinantes.
|
|
US7780963B2
(en)
|
2004-10-25 |
2010-08-24 |
Merck & Co., Inc. |
Anti-ADDL antibodies and uses thereof
|
|
EP1827491A4
(en)
|
2004-11-19 |
2010-07-14 |
Biogen Idec Inc |
TREATMENT OF MULTIPLE SCLEROSIS
|
|
WO2006066089A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
|
PL1752471T3
(pl)
|
2005-01-05 |
2009-04-30 |
F Star Biotechnologische Forschungs Und Entw M B H |
Syntetyczne domeny immunoglobulinowe o właściwościach wiążących konstruowanych w regionach cząsteczki różnych od regionów determinujących komplementarność
|
|
MX2007008785A
(es)
|
2005-01-27 |
2008-02-15 |
Childrens Hosp & Res Ct Oak |
Vacunas de vesicula basadas en gna1870 para proteccion de amplio espectro contra padecimientos causados por neisseria meningitidis.
|
|
NZ608860A
(en)
|
2005-02-14 |
2014-10-31 |
Univ Iowa Res Found |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
|
EP2332408B1
(en)
|
2005-02-17 |
2013-11-13 |
Biogen Idec MA Inc. |
Treating neurological disorders
|
|
JP4942644B2
(ja)
|
2005-02-28 |
2012-05-30 |
株式会社抗体研究所 |
抗ＩｇＳＦ４抗体及びその利用
|
|
KR101213894B1
(ko)
|
2005-03-02 |
2012-12-20 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Ｔｈ2 매개성 병태를 치료하기 위한 ｋｉｍ-1 항체
|
|
ES2429340T3
(es)
|
2005-03-10 |
2013-11-14 |
Morphotek, Inc. |
Anticuerpos anti-mesotelina
|
|
EP2481424A1
(en)
|
2005-03-19 |
2012-08-01 |
Medical Research Council |
Improvements in or relating to treatment and prevention of hepatitis C viral infections
|
|
EP1866339B8
(en)
|
2005-03-25 |
2021-12-01 |
GITR, Inc. |
Gitr binding molecules and uses therefor
|
|
DK1875244T3
(en)
|
2005-03-30 |
2019-04-29 |
Minerva Biotechnologies Corp |
Proliferation of MUC1-Expressing Cells
|
|
CA2610292C
(en)
|
2005-03-30 |
2015-06-02 |
Minerva Biotechnologies Corporation |
Proliferation of muc1 expressing cells
|
|
KR20130114763A
(ko)
|
2005-03-31 |
2013-10-18 |
더 제너럴 하스피탈 코포레이션 |
Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
|
|
RS61229B1
(sr)
|
2005-04-04 |
2021-01-29 |
Biogen Ma Inc |
Metodi evaluacije imunskog odgovora na terapijsko sredstvo
|
|
CA2607455A1
(en)
|
2005-04-22 |
2006-11-02 |
Morphotek, Inc. |
Antibodies with immune effector activity and that internalize in endosialin-positive cells
|
|
US20060239910A1
(en)
|
2005-04-22 |
2006-10-26 |
Morphotek Inc. |
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
|
|
US20090041783A1
(en)
|
2005-04-28 |
2009-02-12 |
Mochida Pharmaceutical Co., Ltd. |
Anti-platelet membrane glycoprotein vi monoclonal antibody
|
|
EP1885396A2
(en)
|
2005-05-04 |
2008-02-13 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
|
CN103130735B
(zh)
|
2005-05-10 |
2016-08-03 |
因塞特控股公司 |
吲哚胺2,3-双加氧酶调节剂及其用法
|
|
WO2006125076A2
(en)
|
2005-05-18 |
2006-11-23 |
Trinity Biosystems, Inc. |
Methods and compositions for immunizing against chlamydia infection
|
|
US8858935B2
(en)
|
2005-05-19 |
2014-10-14 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
BRPI0618160A2
(pt)
|
2005-05-26 |
2011-08-16 |
Univ Colorado |
inibição da via alternativa complemento para tratamento de danos cerebrais traumáticos, danos na medula espinhal e condições relacionadas
|
|
AU2006252830B2
(en)
|
2005-05-27 |
2012-11-22 |
Biogen Ma Inc. |
Tweak binding antibodies
|
|
US8354106B2
(en)
|
2005-06-16 |
2013-01-15 |
The Feinstein Institute For Medical Research |
Antibodies against HMGB1 and fragments thereof
|
|
JP5372500B2
(ja)
|
2005-06-17 |
2013-12-18 |
トレラクス リクイデーティング トラスト |
Ｉｌｔ３結合分子およびその使用
|
|
PL2314623T3
(pl)
*
|
2005-06-21 |
2012-11-30 |
Xoma Us Llc |
Przeciwciała wiążące il-1 beta i ich fragmenty
|
|
CN102875681A
(zh)
|
2005-07-08 |
2013-01-16 |
拜奥根Idec马萨诸塞公司 |
抗-αvβ6抗体及其用途
|
|
US20070026441A1
(en)
|
2005-07-22 |
2007-02-01 |
Olson William C |
Methods for reducing viral load in HIV-1-infected patients
|
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
JP5457671B2
(ja)
|
2005-07-28 |
2014-04-02 |
ノバルティス アーゲー |
Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
|
|
US8193328B2
(en)
|
2005-09-08 |
2012-06-05 |
Philadelphia Health & Education Corporation |
Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
|
|
JP2009509970A
(ja)
|
2005-09-22 |
2009-03-12 |
プロサイ インコーポレイテッド |
酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法
|
|
EP1948680A4
(en)
|
2005-10-28 |
2010-01-13 |
Univ California |
METHOD AND COMPOUNDS FOR DETECTING AND ISOLATING LYMPHOMA CELLS
|
|
CA2627309A1
(en)
|
2005-10-28 |
2007-05-03 |
Meiji Seika Kaisha, Ltd. |
Pseudomonas aeruginosa outer membrane protein pa5158
|
|
TW201337266A
(zh)
|
2005-11-01 |
2013-09-16 |
Abbott Biotech Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
|
WO2007062037A2
(en)
|
2005-11-21 |
2007-05-31 |
Laboratoires Serono Sa |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
|
PL1976877T5
(pl)
†
|
2005-11-30 |
2017-09-29 |
Abbvie Inc |
Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
|
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
|
EP2272497B1
(en)
|
2006-01-18 |
2012-10-03 |
The General Hospital Corporation |
Methods of increasing lymphatic function
|
|
EP1987066B1
(en)
|
2006-02-22 |
2010-12-29 |
University of Zürich |
Methods for treating demyelinating diseases
|
|
JP2009534297A
(ja)
|
2006-03-10 |
2009-09-24 |
ザイモジェネティクス， インコーポレイテッド |
Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法
|
|
US9315578B2
(en)
|
2006-03-23 |
2016-04-19 |
Tohoku Univeristy |
High functional bispecific antibody
|
|
KR20080113239A
(ko)
|
2006-03-30 |
2008-12-29 |
메이지 세이카 가부시키가이샤 |
녹농균의 외막 단백질 ｐａ0427
|
|
CN101454025B
(zh)
|
2006-04-05 |
2014-01-01 |
艾伯维生物技术有限公司 |
抗体纯化
|
|
EP2703010A3
(en)
|
2006-04-10 |
2014-08-06 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of rheumatoid arthritis
|
|
EP2007426A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
|
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
|
AU2007267579B2
(en)
|
2006-05-25 |
2013-05-30 |
Biogen Ma Inc. |
Methods of treating stroke
|
|
BRPI0711229A2
(pt)
|
2006-05-31 |
2013-01-08 |
Astellas Pharma Inc |
anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana
|
|
WO2008042024A2
(en)
|
2006-06-01 |
2008-04-10 |
Elan Pharmaceuticals, Inc. |
Neuroactive fragments of app
|
|
US8101721B2
(en)
|
2006-06-15 |
2012-01-24 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
WO2008094176A2
(en)
|
2006-06-19 |
2008-08-07 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
|
MX2008016335A
(es)
|
2006-06-30 |
2009-01-21 |
Abbott Biotech Ltd |
Dispositivo automatico de inyeccion.
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
JP2009542196A
(ja)
|
2006-07-07 |
2009-12-03 |
インターセル アーゲー |
小型の化膿連鎖球菌抗原およびそれらの使用
|
|
WO2008007648A1
(fr)
|
2006-07-10 |
2008-01-17 |
Institute For Antibodies Co., Ltd. |
Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
|
|
CA2662905A1
(en)
|
2006-07-10 |
2008-01-17 |
Biogen Idec Ma Inc. |
Compositions and methods for inhibiting growth of smad4-deficient cancers
|
|
ES2452067T3
(es)
|
2006-08-04 |
2014-03-31 |
Novartis Ag |
Anticuerpo específico para EPHB3 y usos del mismo
|
|
US9415111B2
(en)
|
2006-08-11 |
2016-08-16 |
Rutgers, The State University Of New Jersey |
Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof
|
|
NZ574138A
(en)
|
2006-08-18 |
2012-01-12 |
Xoma Technology Ltd |
Prlr-specific antibody and uses thereof
|
|
SG192441A1
(nl)
|
2006-09-13 |
2013-08-30 |
Abbott Lab |
|
|
EP2500414A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
|
JPWO2008032833A1
(ja)
|
2006-09-14 |
2010-01-28 |
株式会社医学生物学研究所 |
Ａｄｃｃ活性を増強させた抗体及びその製造方法
|
|
FR2906533B1
(fr)
|
2006-09-28 |
2013-02-22 |
Pf Medicament |
Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
|
|
AU2007315211B2
(en)
|
2006-11-03 |
2013-01-17 |
U3 Pharma Gmbh |
FGFR4 antibodies
|
|
CN103073641B
(zh)
|
2006-11-10 |
2015-01-21 |
株式会社立富泰克 |
在体内具有抗肿瘤活性的抗人Dlk-1抗体
|
|
BRPI0718406A2
(pt)
|
2006-11-17 |
2013-12-17 |
Novartis Ag |
Moléculas de ligação de lingo e uso farmacêutico das mesmas
|
|
EP1923069A1
(en)
|
2006-11-20 |
2008-05-21 |
Intercell AG |
Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
|
|
US8288110B2
(en)
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
|
AU2007329307B2
(en)
|
2006-12-07 |
2012-08-02 |
Novartis Ag |
Antagonist antibodies against EphB3
|
|
EP2102366A4
(en)
|
2006-12-10 |
2010-01-27 |
Dyadic International Inc |
EXPRESSION AND HIGH-DROP SCREENING OF COMPLEX EXPRESSED DNA LIBRARIES IN FADENED MUSHROOMS
|
|
US8440185B2
(en)
|
2006-12-26 |
2013-05-14 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
|
US7931896B2
(en)
|
2006-12-27 |
2011-04-26 |
The Johns Hopkins University |
Compositions and methods for treating inflammation and auto-immune diseases
|
|
EP2118309B1
(en)
|
2006-12-29 |
2015-01-28 |
The Regents of the University of Colorado, a body corporate |
Diagnostic and therapeutic target for autoimmune diseases and uses thereof
|
|
ES2635317T3
(es)
|
2007-01-05 |
2017-10-03 |
University Of Zurich |
Anticuerpo anti-beta-amiloide y sus usos
|
|
AU2008204471B2
(en)
|
2007-01-12 |
2013-02-21 |
Intercell Ag |
Protective proteins of S. agalactiae, combinations thereof and methods of using the same
|
|
US8168415B2
(en)
|
2007-02-07 |
2012-05-01 |
The Regents Of The University Of Colorado |
Axl fusion proteins as Axl tyrosine kinase inhibitors
|
|
PT2130044T
(pt)
|
2007-02-16 |
2017-02-03 |
Genzyme Corp |
Método para a identificação de risco de distúrbio da tiróide
|
|
WO2008103471A2
(en)
|
2007-02-23 |
2008-08-28 |
The Trustees Of Columbia University In The City Of New York |
Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease
|
|
PT3067066T
(pt)
|
2007-02-23 |
2019-06-17 |
Univ California |
Prevenção e tratamento da doença sinucleinopática e amiloidogénica
|
|
JP5558834B2
(ja)
|
2007-02-23 |
2014-07-23 |
ヤンセン アルツハイマー イミュノセラピー |
シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
|
|
RU2488593C2
(ru)
|
2007-03-13 |
2013-07-27 |
Юниверсити Оф Цюрих |
Человеческое опухолеспецифическое моноклональное антитело
|
|
EA019636B1
(ru)
|
2007-03-22 |
2014-05-30 |
Байоджен Айдек Ма Инк. |
Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения
|
|
AU2008237296B2
(en)
|
2007-04-05 |
2013-07-04 |
Eisai, Inc. |
Methods for inhibiting the binding of endosialin to ligands
|
|
EP2392597B1
(en)
|
2007-04-27 |
2014-04-02 |
ZymoGenetics, Inc. |
Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
|
|
CA2685805A1
(en)
|
2007-05-02 |
2008-11-13 |
Intercell Ag |
Klebsiella antigens
|
|
US8962273B2
(en)
|
2007-05-11 |
2015-02-24 |
Genzyme Corporation |
Methods of producing a secreted protein
|
|
US7709215B2
(en)
|
2007-06-01 |
2010-05-04 |
Cytonics Corporation |
Method for diagnosing and treating acute joint injury
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
|
JP2010529999A
(ja)
|
2007-06-14 |
2010-09-02 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
抗体製剤
|
|
WO2008155291A2
(en)
|
2007-06-18 |
2008-12-24 |
Intercell Ag |
Chlamydia antigens
|
|
EP3241842B1
(en)
|
2007-06-26 |
2024-01-31 |
F-star Therapeutics Limited |
Display of binding agents
|
|
CA2690888C
(en)
|
2007-06-27 |
2016-02-09 |
Asubio Pharma Co., Ltd. |
Cancer therapeutic composition comprising antibody against peptide encoded by exon-17 site of periostin
|
|
CN101801413A
(zh)
|
2007-07-12 |
2010-08-11 |
托勒克斯股份有限公司 |
采用gitr结合分子的联合疗法
|
|
EP2014681A1
(en)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
|
US8153595B2
(en)
|
2007-07-13 |
2012-04-10 |
The Johns Hopkins University |
B7-DC variants immunogenic compositions and methods of use thereof
|
|
CN105214085A
(zh)
|
2007-08-02 |
2016-01-06 |
吉联亚生物科技有限公司 |
治疗和诊断纤维化、肿瘤侵入、血管生成和转移的方法和组合物
|
|
US8551751B2
(en)
|
2007-09-07 |
2013-10-08 |
Dyadic International, Inc. |
BX11 enzymes having xylosidase activity
|
|
PT2199390T
(pt)
|
2007-08-30 |
2017-03-15 |
Daiichi Sankyo Co Ltd |
Anticorpo anti-epha2
|
|
JPWO2009031230A1
(ja)
*
|
2007-09-06 |
2010-12-09 |
国立大学法人大阪大学 |
抗ｃｄ２０モノクローナル抗体
|
|
EP2527369A3
(en)
|
2007-09-13 |
2012-12-19 |
University Of Zurich Prorektorat Forschung |
Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
|
|
EP2197911A2
(en)
|
2007-09-14 |
2010-06-23 |
Amgen Inc. |
Homogeneous antibody populations
|
|
RU2482876C2
(ru)
|
2007-10-05 |
2013-05-27 |
Дженентек, Инк. |
Применение антитела против амилоида-бета при глазных заболеваниях
|
|
RU2475499C2
(ru)
|
2007-10-11 |
2013-02-20 |
Дайити Санкио Компани, Лимитед |
Антитело, направленное на белок siglec-15, связанный с остеокластами
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
SG185316A1
(en)
|
2007-10-19 |
2012-11-29 |
Immunas Pharma Inc |
ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF
|
|
EP2217720A4
(en)
|
2007-11-01 |
2010-12-08 |
Univ Iowa Res Found |
RNA LOCUS ANALYSIS TO ASSESS THE STUNNING FOR AMD AND MPGNII
|
|
WO2009056509A1
(en)
|
2007-11-02 |
2009-05-07 |
Novartis Ag |
Improved nogo-a binding molecules and pharmaceutical use thereof
|
|
US20100266604A1
(en)
|
2007-11-09 |
2010-10-21 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
|
NZ585465A
(en)
|
2007-11-12 |
2012-12-21 |
|
Monoclonal antibodies which bind to the extracellular domain of the axl receptor tyrosine kinase
|
|
MX347246B
(es)
|
2007-11-28 |
2017-04-19 |
Univ Pennsylvania |
Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.
|
|
WO2009105084A2
(en)
|
2007-11-28 |
2009-08-27 |
The Trustees Of The University Of Pennsylvania |
Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
|
|
US8815237B2
(en)
|
2007-12-05 |
2014-08-26 |
Massachusetts Institute Of Technology |
Aglycosylated immunoglobulin mutants
|
|
EP2231181B1
(en)
|
2007-12-17 |
2016-02-17 |
Marfl AB |
New vaccine for the treatment of mycobacterium related disorders
|
|
JPWO2009081955A1
(ja)
|
2007-12-25 |
2011-05-06 |
明治製菓株式会社 |
緑膿菌のｉｉｉ型分泌装置構成タンパク質ｐａ１６９８
|
|
CA2710984C
(en)
|
2007-12-28 |
2018-05-29 |
Elan Pharmaceuticals, Inc. |
Treatment and prophylaxis of amyloidosis
|
|
US8591888B2
(en)
|
2008-01-11 |
2013-11-26 |
Synovex Corporation |
Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders
|
|
CA2711882C
(en)
|
2008-01-11 |
2016-07-19 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Improved humanized anti-human .alpha.9-integrin antibody
|
|
CN101918555B
(zh)
|
2008-01-11 |
2013-11-06 |
株式会社遗传科技 |
人源化抗整联蛋白α9抗体及其应用
|
|
AU2009211635B2
(en)
|
2008-02-08 |
2014-06-26 |
Immunas Pharma, Inc. |
Antibody capable of binding specifically to Abeta-oligomer, and use thereof
|
|
WO2009136977A2
(en)
|
2008-03-04 |
2009-11-12 |
The Trustees Of The University Of Pennsylvania |
Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
|
|
BRPI0909180A2
(pt)
|
2008-03-13 |
2016-08-09 |
Biotest Ag |
composição farmacêutica, e, método de tratamento de uma doença autoimune
|
|
WO2009112502A1
(en)
|
2008-03-13 |
2009-09-17 |
Biotest Ag |
Agent for treating disease
|
|
CN102027017A
(zh)
|
2008-03-13 |
2011-04-20 |
生物测试股份公司 |
一种治疗疾病的试剂
|
|
WO2009115531A2
(en)
|
2008-03-17 |
2009-09-24 |
Universitätsklinikum Münster |
Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
|
|
WO2009116670A1
(ja)
|
2008-03-17 |
2009-09-24 |
株式会社リブテック |
in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
|
|
EP2265634A2
(en)
|
2008-03-17 |
2010-12-29 |
Intercell AG |
Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
|
|
US20110028697A1
(en)
|
2008-03-27 |
2011-02-03 |
Takara Bio Inc. |
Prophylactic/therapeutic agent for infectious disease
|
|
BRPI0906903B8
(pt)
|
2008-04-11 |
2021-05-25 |
Seattle Genetics Inc |
anticorpo monoclonal e método de detecção da expressão de cd70
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
EP2300034B1
(en)
|
2008-06-02 |
2018-08-08 |
Dana-Farber Cancer Institute, Inc. |
Pharmaceutical composition for use in treating or preventing multiple myeloma or waldenstrom's macroglobulinemia
|
|
CN102124030B
(zh)
|
2008-06-20 |
2015-06-17 |
国立大学法人冈山大学 |
抗氧化LDL/β2GPI复合物的抗体及其用途
|
|
HUE056007T2
(hu)
|
2008-06-25 |
2022-01-28 |
Novartis Ag |
Nyúl ellenanyagok humanizálása univerzális ellenanyagváz alkalmazásával
|
|
BRPI0914663A2
(pt)
|
2008-06-25 |
2015-10-20 |
Esbatech Alcon Biomed Res Unit |
humanização de anticorpos de coelho usando uma estrutura de anticorpo universal
|
|
DK3444274T3
(da)
|
2008-06-25 |
2021-03-22 |
Novartis Ag |
Stabile og opløselige antistoffer, der hæmmer TNF
|
|
HUE036813T2
(hu)
|
2008-07-08 |
2018-07-30 |
Incyte Holdings Corp |
1,2,5-Oxadiazolok mint indolamin-2,3-dioxigenáz inhibitorok
|
|
AU2010222929B2
(en)
|
2008-07-16 |
2013-07-25 |
Baylor Research Institute |
Antigen presenting cell targeted anti-viral vaccines
|
|
US8993728B2
(en)
|
2008-07-16 |
2015-03-31 |
Medical And Biological Laboratories Co., Ltd. |
Anti-human CLCP1 antibody and use thereof
|
|
KR101196514B1
(ko)
|
2008-08-01 |
2012-11-01 |
가부시키가이샤 아크시스 |
변형성 관절증 치료제 또는 예방제
|
|
US8795981B2
(en)
|
2008-08-08 |
2014-08-05 |
Molecular Devices, Llc |
Cell detection
|
|
US8417011B2
(en)
|
2008-09-18 |
2013-04-09 |
Molecular Devices (New Milton) Ltd. |
Colony detection
|
|
EP2172485A1
(en)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Novel anti CXCR4 antibodies and their use for the treatment of cancer
|
|
CA2739076A1
(en)
|
2008-10-02 |
2010-04-08 |
Celtaxsys, Inc. |
Methods of modulating the negative chemotaxis of immune cells
|
|
WO2010042891A2
(en)
|
2008-10-09 |
2010-04-15 |
Minerva Biotechnologies Corporation |
Method for inducing pluripotency in cells
|
|
US8821880B2
(en)
|
2008-10-29 |
2014-09-02 |
China Synthetic Rubber Corporation |
Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
DK2350269T3
(en)
|
2008-10-31 |
2015-12-07 |
Univ Pennsylvania |
ABE ADENOVIRUS WITH SADV-46 HEXONCAPSIDE PROTEINS AND APPLICATIONS THEREOF
|
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
|
KR101781228B1
(ko)
|
2008-12-19 |
2017-09-22 |
바이오겐 인터내셔널 뉴로사이언스 게엠베하 |
인간 항-알파-시누클레인 자가항체
|
|
US8313915B2
(en)
|
2009-01-21 |
2012-11-20 |
Gundersen Lutheran Medical Foundation, Inc. |
Early detection of canine lyme disease by specific peptides and antibodies
|
|
WO2010085590A1
(en)
|
2009-01-23 |
2010-07-29 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
|
|
WO2010089340A2
(en)
|
2009-02-05 |
2010-08-12 |
Intercell Ag |
Peptides protective against e. faecalis, methods and uses relating thereto
|
|
EP2405938A2
(en)
|
2009-02-13 |
2012-01-18 |
Intercell AG |
Nontypable haemophilus influenzae antigens
|
|
WO2010096658A1
(en)
|
2009-02-19 |
2010-08-26 |
The Cleveland Clinic Foundation |
Corin as a marker for heart failure
|
|
JP5883653B2
(ja)
|
2009-03-10 |
2016-03-15 |
ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ |
抗原提示細胞ターゲティング抗ウイルスワクチン
|
|
ES2584956T3
(es)
|
2009-03-10 |
2016-09-30 |
Baylor Research Institute |
Anticuerpos anti-CD40 y usos de los mismos
|
|
WO2010109924A1
(ja)
|
2009-03-25 |
2010-09-30 |
国立大学法人東北大学 |
Ｌｈ型二重特異性抗体
|
|
US8575316B2
(en)
|
2009-04-09 |
2013-11-05 |
Daiichi Sankyo Company, Limited |
Anti-Siglec-15 antibody
|
|
EP2990051B1
(en)
|
2009-04-10 |
2016-10-26 |
Tufts Medical Center, Inc. |
Par-1 activation by metalloproteinase-1 (mmp-1)
|
|
JP5812418B2
(ja)
|
2009-04-17 |
2015-11-11 |
イムナス・ファーマ株式会社 |
Ａβオリゴマーに特異的に結合する抗体およびその利用
|
|
EP2246364A1
(en)
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Anti CXCR4 antibodies for the treatment of HIV
|
|
SG175279A1
(en)
|
2009-04-29 |
2011-11-28 |
Abbott Biotech Ltd |
Automatic injection device
|
|
EP2270053A1
(en)
|
2009-05-11 |
2011-01-05 |
U3 Pharma GmbH |
Humanized AXL antibodies
|
|
EP2435559A1
(en)
|
2009-05-29 |
2012-04-04 |
The Trustees Of The University Of Pennsylvania |
Simian adenovirus 41 and uses thereof
|
|
EP2260864A1
(en)
|
2009-06-10 |
2010-12-15 |
University of Melbourne |
Therapeutic applications
|
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
|
|
JP5755647B2
(ja)
|
2009-07-24 |
2015-07-29 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物
|
|
WO2011012646A2
(en)
|
2009-07-28 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Non-invasive in vivo optical imaging method
|
|
AU2010280981B2
(en)
|
2009-08-05 |
2016-01-28 |
Nexigen Gmbh |
Human HCV-interacting proteins and methods of use
|
|
WO2011024114A1
(en)
|
2009-08-25 |
2011-03-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Targeting extracellular matrix molecules for the treatment of cancer
|
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗ｃｄｃｐ１抗體
|
|
CA2772204A1
(en)
|
2009-08-31 |
2011-03-03 |
Amplimmune, Inc. |
Methods and compositions for the inhibition of transplant rejection
|
|
EP2477647B1
(en)
|
2009-09-14 |
2016-01-13 |
The Regents of the University of Colorado |
Modulation of yeast-based immunotherapy products and responses
|
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
EP2308897A1
(en)
|
2009-10-09 |
2011-04-13 |
Pierre Fabre Medicament |
Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
|
|
EP3349010B1
(en)
|
2009-10-11 |
2024-08-28 |
Biogen MA Inc. |
Anti-vla-4 related assays
|
|
WO2011062112A1
(ja)
|
2009-11-18 |
2011-05-26 |
国立大学法人東北大学 |
ヒト型化抗ｅｇｆｒ抗体可変領域の高機能性変異体
|
|
EP2332929A1
(en)
|
2009-11-25 |
2011-06-15 |
ArisGen SA |
Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
|
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
|
US9872905B2
(en)
|
2009-12-01 |
2018-01-23 |
President And Fellows Of Harvard College |
Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186)
|
|
AU2010330907A1
(en)
|
2009-12-16 |
2012-06-14 |
Bosch, Phillip |
Methods of treating interstitial cystitis
|
|
WO2011088193A2
(en)
|
2010-01-13 |
2011-07-21 |
University Of Medicine And Dentistry Of New Jersey |
Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
|
|
CA2787755A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
|
US9023997B2
(en)
|
2010-01-20 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Anti-ILT5 antibodies and ILT5-binding antibody fragments
|
|
JP2012246222A
(ja)
|
2010-01-29 |
2012-12-13 |
Axis Inc |
変形性関節症治療剤または予防剤を製造するための使用
|
|
KR101684246B1
(ko)
|
2010-01-29 |
2016-12-08 |
가부시키가이샤 아크시스 |
변형성 관절증 치료제를 포함하는 주사제
|
|
US20130011407A1
(en)
|
2010-01-29 |
2013-01-10 |
Axis Inc. |
Pharmaceutical composition for treatment or prevention of osteoarthritis, and method of production therefor
|
|
CN102959088A
(zh)
|
2010-02-02 |
2013-03-06 |
艾博特生物技术有限公司 |
用于预测对TNF-α抑制剂治疗的反应性的方法和组合物
|
|
ES2668645T3
(es)
|
2010-02-08 |
2018-05-21 |
Agensys, Inc. |
Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B
|
|
JP2013520173A
(ja)
|
2010-02-18 |
2013-06-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
インテグリンαｖβ８中和抗体
|
|
EP2544688B1
(en)
|
2010-03-02 |
2016-09-07 |
President and Fellows of Harvard College |
Methods and compositions for treatment of angelman syndrome
|
|
EP3056510B1
(en)
|
2010-03-03 |
2018-10-03 |
The University Of British Columbia |
Oligomer-specific amyloid beta epitope and antibodies
|
|
WO2011117392A2
(en)
|
2010-03-26 |
2011-09-29 |
Universitaetsklinikum Muenster |
Substitute therapy for glucocorticoids
|
|
EP2371863A1
(en)
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Humanized anti CXCR4 antibodies for the treatment of cancer
|
|
RU2684724C2
(ru)
|
2010-04-09 |
2019-04-11 |
Критикал Кэа Дайэгностикс, Инк. |
Антитела против растворимого st-2 человека и способы анализа
|
|
PT3202789T
(pt)
|
2010-04-16 |
2020-06-16 |
Biogen Ma Inc |
Anticorpos anti-vla-4
|
|
CN104906656B
(zh)
|
2010-04-21 |
2020-01-10 |
艾伯维生物技术有限公司 |
用于治疗药剂的受控输送的可佩戴自动注射装置
|
|
RU2012148816A
(ru)
|
2010-05-07 |
2014-06-20 |
Ф. Хоффманн-Ля Рош Аг |
Метод диагностики для определения клеток ex vivo
|
|
JP5859434B2
(ja)
|
2010-05-17 |
2016-02-10 |
株式会社カイオム・バイオサイエンス |
ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＴＲＯＰ−２抗体
|
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
|
JP5619162B2
(ja)
|
2010-07-08 |
2014-11-05 |
本田技研工業株式会社 |
高周波加熱用コイル
|
|
BR112013000796B1
(pt)
|
2010-07-14 |
2021-08-31 |
Merck Sharp & Dohme Corp |
Anticorpo isolado ou um fragmento de ligação ao antígeno, composição farmacêutica, métodos para inibir a montagem de ligantes difusíveis derivados de ß-amiloide, para inibir a fosforilação de proteína tau em ser202/thr205, para identificar um suposto agente terapêutico, para detectar ligantes difusíveis derivados de ß-amiloide e para diagnosticar uma doença associada aos ligantes difusíveis derivados de ß-amiloide, e, kit para detectar ligantes difusíveis derivados de ß-amiloide
|
|
EP3345925A3
(en)
|
2010-07-15 |
2018-09-26 |
Adheron Therapeutics, Inc. |
Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
|
|
AU2011283669A1
(en)
|
2010-07-29 |
2013-02-07 |
Eleven Biotherapeutics, Inc. |
Chimeric IL-1 receptor type I agonists and antagonists
|
|
JP6081356B2
(ja)
|
2010-07-30 |
2017-02-15 |
エーシー イミューン エス．エー． |
安全で機能的なヒト化抗βアミロイド抗体
|
|
JP2012034668A
(ja)
|
2010-08-12 |
2012-02-23 |
Tohoku Univ |
ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
|
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
|
EP2609431B1
(en)
|
2010-08-27 |
2017-05-10 |
University of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
|
WO2012025633A1
(en)
|
2010-08-27 |
2012-03-01 |
University Of Zurich |
A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
|
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
|
US20120244141A1
(en)
|
2010-09-28 |
2012-09-27 |
Boehringer Ingelheim International Gmbh |
Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
|
|
US8497138B2
(en)
|
2010-09-30 |
2013-07-30 |
Genetix Limited |
Method for cell selection
|
|
US9675693B2
(en)
|
2010-09-30 |
2017-06-13 |
Riken |
Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
|
|
US8940272B2
(en)
|
2010-10-11 |
2015-01-27 |
University Of Zurich |
Human anti-tau antibodies
|
|
RU2600444C2
(ru)
|
2010-10-13 |
2016-10-20 |
Янссен Байотек, Инк. |
Человеческие антитела к онкостатину м и способы их применения
|
|
WO2012052230A1
(en)
|
2010-10-18 |
2012-04-26 |
Mediapharma S.R.L. |
Erbb3 binding antibody
|
|
AR083495A1
(es)
|
2010-10-22 |
2013-02-27 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles
|
|
AU2011316917B2
(en)
|
2010-10-22 |
2016-02-25 |
Seagen Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
|
|
HUE050713T2
(hu)
|
2010-10-25 |
2020-12-28 |
Biogen Ma Inc |
Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával
|
|
KR20140009174A
(ko)
|
2010-10-27 |
2014-01-22 |
피에르 파브르 메디카먼트 |
Hiv의 치료를 위한 항체들
|
|
WO2012057288A1
(ja)
|
2010-10-29 |
2012-05-03 |
第一三共株式会社 |
新規抗ｄｒ５抗体
|
|
EP2640425A2
(en)
|
2010-11-18 |
2013-09-25 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
|
TWI589587B
(zh)
|
2010-11-19 |
2017-07-01 |
衛材Ｒ＆Ｄ企管股份有限公司 |
中和性抗－ｃｃｌ２０抗體
|
|
WO2012071318A2
(en)
|
2010-11-23 |
2012-05-31 |
The Trustees Of The University Of Pennsylvania |
Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
|
|
AU2011343161B2
(en)
|
2010-12-17 |
2017-02-02 |
Neurimmune Holding Ag |
Human anti-SOD1 antibodies
|
|
WO2012090939A1
(ja)
|
2010-12-27 |
2012-07-05 |
国立大学法人名古屋大学 |
受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法
|
|
ES2617983T3
(es)
|
2011-01-10 |
2017-06-20 |
Ct Atlantic Ltd. |
Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores
|
|
EP3252076B1
(en)
|
2011-01-14 |
2019-09-04 |
The Regents Of The University Of California |
Diagnostic use of antibodies against ror-1 protein
|
|
EP4245219A3
(en)
|
2011-01-24 |
2023-11-01 |
AbbVie Biotechnology Ltd. |
Automatic injection devices having overmolded gripping surfaces
|
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
|
WO2012110843A1
(en)
|
2011-02-18 |
2012-08-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
|
|
US20140044644A1
(en)
|
2011-02-21 |
2014-02-13 |
University Of Zurich |
Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
|
|
EP2683413A1
(en)
|
2011-03-07 |
2014-01-15 |
F.Hoffmann-La Roche Ag |
In vivo selection of therapeutically active antibodies
|
|
US20140099264A1
(en)
|
2011-03-07 |
2014-04-10 |
F. Hoffman-La Roche Ag |
Means and methods for in vivo testing of therapeutic antibodies
|
|
WO2012120130A1
(en)
|
2011-03-09 |
2012-09-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods to characterize patients suffering from hemolysis
|
|
WO2012125680A1
(en)
|
2011-03-16 |
2012-09-20 |
Novartis Ag |
Methods of treating vasculitis using an il-17 binding molecule
|
|
JP5955871B2
(ja)
|
2011-03-17 |
2016-07-20 |
ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｔｃｒアルファ／ベータを枯渇させた細胞調製物
|
|
EP4086338A1
(en)
|
2011-03-17 |
2022-11-09 |
Minerva Biotechnologies Corporation |
Method for making pluripotent stem cells
|
|
AR085573A1
(es)
|
2011-03-25 |
2013-10-09 |
Baylor Res Inst |
Composiciones y metodos de inmunizacion contra el virus de la hepatitis c
|
|
TW201249867A
(en)
|
2011-04-01 |
2012-12-16 |
Astellas Pharma Inc |
Novel anti-human il-23 receptor antibody
|
|
JP6066995B2
(ja)
|
2011-04-21 |
2017-01-25 |
アッヴィ・インコーポレイテッド |
装着型自動注射装置
|
|
TWI561531B
(en)
|
2011-04-25 |
2016-12-11 |
Daiichi Sankyo Co Ltd |
Anti b7-h3 antibody
|
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
|
TWI698254B
(zh)
|
2011-05-02 |
2020-07-11 |
美商千禧製藥公司 |
抗-α4β7抗體之調配物
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
WO2012154889A1
(en)
|
2011-05-09 |
2012-11-15 |
The Cleveland Clinic Foundation |
Serum s100b and uses thereof
|
|
WO2012163848A1
(en)
|
2011-05-27 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of crohn's disease
|
|
EP2530088A1
(en)
|
2011-05-30 |
2012-12-05 |
Klinikum rechts der Isar der Technischen Universität München |
Means and methods for diagnosing and treating multiple sclerosis
|
|
WO2012163771A1
(en)
|
2011-06-03 |
2012-12-06 |
Ct Atlantic Ltd. |
Magea3 binding antibodies
|
|
WO2012163769A1
(en)
|
2011-06-03 |
2012-12-06 |
Ct Atlantic Ltd. |
Magea3 binding antibodies
|
|
CA2836373A1
(en)
|
2011-06-06 |
2012-12-13 |
Neotope Biosciences Limited |
Mcam antagonists and methods of treatment
|
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
|
CN103796679B
(zh)
|
2011-06-23 |
2016-10-19 |
比奥根国际神经科学公司 |
抗-α突触核蛋白结合分子
|
|
DE202011103324U1
(de)
|
2011-07-12 |
2012-01-02 |
Nekonal S.A.R.L. |
Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
|
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
|
WO2013014262A1
(en)
|
2011-07-27 |
2013-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating myhre syndrome
|
|
US8986952B2
(en)
|
2011-08-11 |
2015-03-24 |
Astellas Pharma Inc. |
Anti-human NGF antibody
|
|
US20140242085A1
(en)
|
2011-08-12 |
2014-08-28 |
Medical & Biological Laboratories Co., Ltd. |
Methods and composition for testing, preventing, and treating aspergillus fumigatus infection
|
|
US20140271680A1
(en)
|
2011-08-12 |
2014-09-18 |
Universite Paris-Est Creteil Val De Marne |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
SG10201912964PA
(en)
|
2011-09-19 |
2020-02-27 |
Axon Neuroscience Se |
Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
|
|
GB2495115A
(en)
*
|
2011-09-29 |
2013-04-03 |
Oxford Plastic Sys Ltd |
Base for supporting temporary fence panels or posts.
|
|
AR088048A1
(es)
|
2011-10-04 |
2014-05-07 |
Univ Columbia |
Señuelos notch1 humanos
|
|
WO2013050540A1
(en)
|
2011-10-05 |
2013-04-11 |
University Of Bremen |
Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
|
|
WO2013050441A1
(en)
|
2011-10-05 |
2013-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
|
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
|
WO2013055911A1
(en)
|
2011-10-14 |
2013-04-18 |
Dana-Farber Cancer Institute, Inc. |
Znf365/zfp365 biomarker predictive of anti-cancer response
|
|
JP6466170B2
(ja)
|
2011-10-17 |
2019-02-06 |
ミネルバ バイオテクノロジーズ コーポレーション |
幹細胞の増殖及び誘導用の培地
|
|
EP2768971A1
(en)
|
2011-10-20 |
2014-08-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the detection and the treatment of cardiac remodeling
|
|
EP2589609A1
(en)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigen binding protein and its use as addressing product for the treatment of cancer
|
|
EP2782933A1
(en)
|
2011-11-22 |
2014-10-01 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for reducing airway hyperresponse
|
|
US9427464B2
(en)
|
2011-11-22 |
2016-08-30 |
Chiome Bioscience Inc. |
Anti-human TROP-2 antibody having an antitumor activity in vivo
|
|
WO2013079487A1
(en)
|
2011-11-28 |
2013-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical composition for use in the treatment of dysfunction associated with aging
|
|
EP2602621A1
(en)
|
2011-12-08 |
2013-06-12 |
Julius-Maximilians-Universität Würzburg |
LASP-1, a novel urinary marker for transitional cell carcinoma detection
|
|
JP2015501654A
(ja)
*
|
2011-12-13 |
2015-01-19 |
ノルディック ナノベクター アーエス |
治療用キメラ型抗ｃｄ３７抗体ｈｈ１
|
|
US20150030602A1
(en)
|
2011-12-23 |
2015-01-29 |
Phenoquest Ag |
Antibodies for the treatment and diagnosis of affective and anxiety disorders
|
|
FR2984750B1
(fr)
|
2011-12-23 |
2014-01-10 |
Lfb Biotechnologies |
Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
|
|
AU2013206788B2
(en)
|
2011-12-28 |
2017-11-30 |
Immunoqure Ag |
Method of providing monoclonal auto-antibodies with desired specificity
|
|
EP2797632A1
(en)
|
2012-01-01 |
2014-11-05 |
QBI Enterprises Ltd. |
Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
|
|
AU2013216863B2
(en)
|
2012-02-10 |
2018-09-06 |
Seagen Inc. |
Detection and treatment of CD30+ cancers
|
|
US10316095B2
(en)
|
2012-02-16 |
2019-06-11 |
Santarus, Inc. |
Antibody formulations
|
|
IN2014KN01772A
(nl)
|
2012-02-23 |
2015-10-23 |
U3 Pharma Gmbh |
|
|
PT2821416T
(pt)
|
2012-02-28 |
2018-12-14 |
Astellas Pharma Inc |
Anticorpo de recetor il-23 anti- humano inovador
|
|
BR122020002414B1
(pt)
|
2012-03-15 |
2022-03-03 |
Janssen Biotech, Inc |
Uso de anticorpos anti-cd27 humanos
|
|
EP2828284B1
(en)
|
2012-03-20 |
2019-05-08 |
Biogen MA Inc. |
Jcv neutralizing antibodies
|
|
MX2014011828A
(es)
|
2012-03-30 |
2014-12-10 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada.
|
|
JPWO2013147212A1
(ja)
|
2012-03-30 |
2015-12-14 |
第一三共株式会社 |
新規抗Ｓｉｇｌｅｃ−１５抗体
|
|
ES2702278T3
(es)
|
2012-04-01 |
2019-02-28 |
Technion Res & Dev Foundation |
Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
|
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
|
CA2869394A1
(en)
|
2012-04-02 |
2013-10-10 |
Gundersen Lutheran Health System, Inc. |
Reagents, methods, and kits for the classification of cancer
|
|
ES2831309T3
(es)
|
2012-04-09 |
2021-06-08 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-FGFR2
|
|
DK2841457T3
(da)
|
2012-04-27 |
2019-07-22 |
Daiichi Sankyo Co Ltd |
Antistof imod ROBO4
|
|
US9062120B2
(en)
|
2012-05-02 |
2015-06-23 |
Janssen Biotech, Inc. |
Binding proteins having tethered light chains
|
|
JP6263117B2
(ja)
|
2012-05-11 |
2018-01-17 |
公益財団法人微生物化学研究会 |
抗ｃｘａｄｒ抗体
|
|
MX362497B
(es)
|
2012-05-15 |
2019-01-21 |
Eisai Inc |
Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
|
|
SG10201609511XA
(en)
|
2012-05-18 |
2016-12-29 |
Univ Pennsylvania |
Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
|
|
WO2013174834A1
(en)
|
2012-05-22 |
2013-11-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating focal segmental glomerulosclerosis
|
|
US9290564B2
(en)
|
2012-05-24 |
2016-03-22 |
Mountgate Group Limited |
Compositions and methods related to the prevention and treatment of rabies infection
|
|
WO2014011984A1
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Toxicity management for anti-tumor activity of cars
|
|
EP2875049B1
(en)
|
2012-07-18 |
2018-12-26 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for preventing and treating chronic kidney disease (ckd)
|
|
RU2015105588A
(ru)
|
2012-07-19 |
2016-09-10 |
Редвуд Байосайнс, Инк. |
Антитело, специфическое к cd22, и способы его применения
|
|
JP6248037B2
(ja)
|
2012-07-30 |
2017-12-13 |
国立大学法人名古屋大学 |
ヒトミッドカインに対するモノクローナル抗体
|
|
CN109369808B
(zh)
|
2012-08-24 |
2023-11-07 |
加利福尼亚大学董事会 |
用于治疗ror1癌症并抑制转移的抗体和疫苗
|
|
TW201922795A
(zh)
|
2012-09-10 |
2019-06-16 |
愛爾蘭商尼歐托普生物科學公司 |
抗ｍｃａｍ抗體及相關使用方法
|
|
WO2014042251A1
(ja)
|
2012-09-13 |
2014-03-20 |
中外製薬株式会社 |
遺伝子ノックイン非ヒト動物
|
|
EP2711016A1
(en)
|
2012-09-21 |
2014-03-26 |
Covagen AG |
Novel IL-17A binding molecules and medical uses thereof
|
|
WO2014054820A1
(ja)
|
2012-10-03 |
2014-04-10 |
株式会社リブテック |
in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
|
|
CA2886120A1
(en)
|
2012-10-08 |
2014-04-17 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
|
CN109081871B
(zh)
|
2012-10-11 |
2023-07-14 |
第一三共株式会社 |
抗体－药物偶联物
|
|
DE102012020496A1
(de)
|
2012-10-18 |
2014-04-24 |
Charité - Universitätsmedizin Berlin |
Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
|
|
WO2014061277A1
(ja)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
|
|
EP2911681A1
(en)
|
2012-10-26 |
2015-09-02 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
|
|
WO2014068079A1
(en)
|
2012-11-01 |
2014-05-08 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
CA2890265C
(en)
|
2012-11-05 |
2023-01-17 |
Pierre Fabre Medicament |
Antigen binding proteins and their use as addressing product for the treatment of cancer
|
|
JP6445446B2
(ja)
|
2012-11-08 |
2018-12-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
骨転移の治療のための方法及び医薬組成物
|
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
|
AU2013359419B2
(en)
|
2012-12-10 |
2018-03-15 |
Biogen Ma Inc. |
Anti-blood dendritic cell antigen 2 antibodies and uses thereof
|
|
WO2014096672A1
(fr)
|
2012-12-17 |
2014-06-26 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
|
US10024844B2
(en)
|
2012-12-20 |
2018-07-17 |
Hospital For Special Surgery |
Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
|
|
SI2935326T1
(sl)
|
2012-12-21 |
2021-03-31 |
Biogen Ma Inc. |
Človeška protitelesa ANTI-TAU
|
|
US9771413B2
(en)
|
2012-12-31 |
2017-09-26 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
|
EP2752426A1
(en)
|
2013-01-03 |
2014-07-09 |
Covagen AG |
Human serum albumin binding compounds and fusion proteins thereof
|
|
MX2015009547A
(es)
|
2013-01-28 |
2015-11-25 |
Evec Inc |
Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo.
|
|
WO2014118317A1
(en)
|
2013-02-01 |
2014-08-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and preventing metastasis in triple negative breast cancers
|
|
US9932396B2
(en)
|
2013-02-08 |
2018-04-03 |
Medical & Biological Laboratories Co., Ltd. |
Antibody against human NRG1 protein
|
|
CA2894918A1
(en)
|
2013-02-15 |
2014-08-21 |
Esbatech - A Novartis Company Llc |
Acceptor framework for cdr grafting
|
|
CA2896174A1
(en)
|
2013-02-20 |
2014-08-28 |
Esbatech - A Novartis Company Llc |
Acceptor framework for cdr grafting
|
|
FR3004184B1
(fr)
|
2013-02-26 |
2016-03-18 |
Agronomique Inst Nat Rech |
Anticorps anti-gluten desamide et utilisations.
|
|
EP3339327A3
(en)
|
2013-02-28 |
2018-09-19 |
National Cancer Center |
Antibody against insoluble fibrin
|
|
WO2014136910A1
(ja)
|
2013-03-08 |
2014-09-12 |
国立大学法人大阪大学 |
ペリオスチンのＥｘｏｎ－２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物
|
|
JP6450364B2
(ja)
|
2013-03-13 |
2019-01-09 |
セセン バイオ， インコーポレイテッド |
眼送達のためのキメラサイトカイン製剤
|
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
WO2014151917A1
(en)
|
2013-03-14 |
2014-09-25 |
Ffe Therapeutics Llc |
Compositions and methods for treating angiogenesis-related disorders
|
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
|
MX2015011670A
(es)
|
2013-03-15 |
2016-03-31 |
Biogen Ma Inc |
Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
|
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
|
EP2976361B1
(en)
|
2013-03-18 |
2018-07-18 |
BiocerOX Products B.V. |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
EP3747907A3
(en)
|
2013-04-01 |
2021-02-24 |
The Regents of the University of California |
Methods and compositions for treating and preventing disease associated with avb8 integrin
|
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
CN107460201A
(zh)
|
2013-05-08 |
2017-12-12 |
科济生物医药（上海）有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
|
WO2014205374A1
(en)
|
2013-06-20 |
2014-12-24 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosing pancreatic cancer
|
|
CN112358548B
(zh)
|
2013-07-03 |
2024-10-25 |
因美诺克股份公司 |
人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法
|
|
WO2015001082A1
(en)
|
2013-07-05 |
2015-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
|
EP3016683B1
(en)
|
2013-07-05 |
2020-06-24 |
University of Washington through its Center for Commercialization |
Soluble mic neutralizing monoclonal antibody for treating cancer
|
|
TWI635097B
(zh)
|
2013-08-09 |
2018-09-11 |
日商安斯泰來製藥股份有限公司 |
新穎抗人類ｔｓｌｐ受體抗體
|
|
EP3055695A1
(en)
|
2013-09-12 |
2016-08-17 |
Institut National de la Santé et de la Recherche Médicale |
Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
|
|
AU2014322988B2
(en)
|
2013-09-20 |
2018-12-06 |
Westfaelische Wilhelms-Universitaet Muenster |
Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy
|
|
CN105764923A
(zh)
|
2013-09-24 |
2016-07-13 |
范因斯坦医学研究院 |
对可冷诱导的rna结合蛋白活性进行抑制的肽
|
|
WO2015048531A1
(en)
|
2013-09-26 |
2015-04-02 |
Beth Israel Deaconess Medical Center, Inc. |
Inhibition of sgk1 in the treatment of heart conditions
|
|
TW201602341A
(zh)
|
2013-09-30 |
2016-01-16 |
第一三共股份有限公司 |
抗ｌｐｓ ｏ１１抗體
|
|
EP3052131B1
(en)
|
2013-10-01 |
2018-12-05 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
|
KR20220019839A
(ko)
|
2013-10-08 |
2022-02-17 |
다이이찌 산쿄 가부시키가이샤 |
항 fgfr2 항체와 타제의 조합
|
|
SI3065774T1
(sl)
|
2013-11-06 |
2021-11-30 |
Janssen Biotech, Inc. |
Protitelesa proti CCL17
|
|
WO2015068781A1
(ja)
|
2013-11-06 |
2015-05-14 |
国立大学法人大阪大学 |
インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
|
|
WO2015071701A1
(en)
|
2013-11-15 |
2015-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pancreatic cancers
|
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
|
CN105829534B
(zh)
|
2013-12-24 |
2021-08-03 |
安斯泰来制药株式会社 |
抗人bdca-2抗体
|
|
DK3088419T3
(en)
|
2013-12-25 |
2019-01-28 |
Daiichi Sankyo Co Ltd |
ANTI-TROP2 ANTIBODY-MEDICINE CONJUGATE
|
|
EP4101461A1
(en)
|
2014-01-09 |
2022-12-14 |
Hadasit Medical Research Services and Development Ltd. |
Improved cell compositions and methods for cancer therapy
|
|
CN106103483A
(zh)
|
2014-01-13 |
2016-11-09 |
贝勒研究院 |
抗hpv和hpv相关的疾病的新疫苗
|
|
CN104774264B
(zh)
|
2014-01-15 |
2018-09-14 |
上海易乐生物技术有限公司 |
抗人proBDNF单克隆抗体及其在疼痛中的作用
|
|
KR102557062B1
(ko)
|
2014-01-31 |
2023-07-18 |
다이이찌 산쿄 가부시키가이샤 |
항-her2 항체-약물 접합체
|
|
WO2015124570A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of influenza a virus infection
|
|
EP3108255B1
(en)
|
2014-02-18 |
2020-08-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
|
|
EP2915543B1
(en)
|
2014-03-04 |
2018-05-09 |
Albert-Ludwigs-Universität Freiburg |
Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies
|
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
|
EP3122768A2
(en)
|
2014-03-27 |
2017-02-01 |
Yeda Research and Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
|
TW202428616A
(zh)
|
2014-04-10 |
2024-07-16 |
日商第一三共股份有限公司 |
抗ｈｅｒ３抗體－藥物結合物之製造方法
|
|
EP3132053B1
(en)
|
2014-04-15 |
2020-09-30 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Differential diagnosis of eczema and psoriasis
|
|
EP3134546A4
(en)
|
2014-04-24 |
2017-12-06 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
|
ES2727103T3
(es)
|
2014-04-25 |
2019-10-14 |
Pf Medicament |
Conjugado anticuerpo-fármaco para IGF-1R y su utilización para el tratamiento del cáncer
|
|
WO2015162293A1
(en)
|
2014-04-25 |
2015-10-29 |
Pierre Fabre Medicament |
Antibody-drug-conjugate and its use for the treatment of cancer
|
|
PL3134438T3
(pl)
|
2014-04-25 |
2021-04-06 |
Pierre Fabre Médicament |
Przeciwciało IGF-1R i jego zastosowanie jako nośnika kierującego do leczenia nowotworów
|
|
MD20160130A2
(ro)
|
2014-04-27 |
2017-04-30 |
Ccam Biotherapeutics Ltd. |
Anticorpi umanizaţi contra CEACAM1
|
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
CA2953807A1
(en)
|
2014-06-26 |
2015-12-30 |
Yale University |
Compositions and methods to regulate renalase in the treatment of diseases and disorders
|
|
CN112979828A
(zh)
|
2014-07-17 |
2021-06-18 |
恺兴生命科技(上海)有限公司 |
靶向cld18a2的t淋巴细胞及其制备方法和应用
|
|
EP3169691B1
(en)
|
2014-07-17 |
2020-09-02 |
The Trustees Of The University Of Pennsylvania |
Methods for using exosomes to monitor transplanted organ status
|
|
EP3171896A4
(en)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
|
CA2954738A1
(en)
|
2014-07-29 |
2016-02-04 |
Neurimmune Holding Ag |
Human-derived anti-huntingtin (htt) antibodies and uses thereof
|
|
MY180054A
(en)
|
2014-09-30 |
2020-11-20 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
|
EP3201226A2
(en)
|
2014-10-03 |
2017-08-09 |
Massachusetts Institute of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
|
AU2015328411C1
(en)
|
2014-10-06 |
2022-03-03 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
WO2016057651A1
(en)
|
2014-10-09 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable il-2 dose regimen for treating immune disorders
|
|
WO2016081835A2
(en)
|
2014-11-21 |
2016-05-26 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
|
WO2016087889A1
(en)
|
2014-12-03 |
2016-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers
|
|
EP3256148A1
(en)
|
2015-02-12 |
2017-12-20 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
|
|
WO2016144673A1
(en)
|
2015-03-06 |
2016-09-15 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
|
|
EP3067062A1
(en)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
|
CN108368169A
(zh)
|
2015-03-18 |
2018-08-03 |
约翰霍普金斯大学 |
靶向钾通道kcnk9的新的单克隆抗体抑制剂
|
|
EP3273981B1
(en)
|
2015-03-24 |
2020-04-29 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of diabetes
|
|
EP3277309A1
(en)
|
2015-04-03 |
2018-02-07 |
Alienor Farma |
Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
|
|
US10851176B2
(en)
|
2015-04-13 |
2020-12-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A
|
|
WO2016170027A1
(en)
|
2015-04-22 |
2016-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
|
|
EA201792660A1
(ru)
|
2015-06-01 |
2018-05-31 |
Медиджин Иммьюнотерапиз Гмбх |
Библиотека т-клеточных рецепторов
|
|
CA2987871A1
(en)
|
2015-06-01 |
2016-12-08 |
Medigene Immunotherapies Gmbh |
Method for generating antibodies against t cell receptor
|
|
BR112017025332A2
(pt)
|
2015-06-01 |
2018-07-31 |
Medigene Immunotherapies Gmbh |
anticorpos específicos de receptor de célula t
|
|
EP3310800B1
(en)
|
2015-06-19 |
2021-11-17 |
Centurion BioPharma Corporation |
Delivery systems for controlled drug release
|
|
US20180161429A1
(en)
|
2015-06-26 |
2018-06-14 |
Beth Israel Deaconess Medical Center Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
|
WO2017002776A1
(ja)
|
2015-06-29 |
2017-01-05 |
第一三共株式会社 |
抗体－薬物コンジュゲートの選択的製造方法
|
|
CN107921128B
(zh)
|
2015-08-05 |
2022-04-26 |
詹森生物科技公司 |
抗cd154抗体及其使用方法
|
|
WO2017046335A1
(en)
|
2015-09-18 |
2017-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
|
|
ES2940360T3
(es)
|
2015-09-22 |
2023-05-05 |
Inst Nat Sante Rech Med |
Polipéptidos capaces de inhibir la unión entre leptina y neuropilina-1
|
|
IL288784B2
(en)
|
2015-09-24 |
2023-10-01 |
Daiichi Sankyo Co Ltd |
Antibodies against GARP, nucleotides encoding them, and vectors, cells and preparations containing them, methods for their preparation and uses thereof
|
|
US20190048089A1
(en)
|
2015-09-30 |
2019-02-14 |
Janssen Biotech, Inc. |
Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use
|
|
WO2017061615A1
(ja)
|
2015-10-08 |
2017-04-13 |
国立大学法人名古屋大学 |
キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法
|
|
WO2017064716A1
(en)
|
2015-10-13 |
2017-04-20 |
Rappaport Family Institute For Research |
Heparanase-neutralizing monoclonal antibodies
|
|
EP3362082A1
(en)
|
2015-10-16 |
2018-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
|
AU2016344663B2
(en)
|
2015-10-26 |
2023-09-07 |
Pierre Fabre Medicament |
Composition for the treatment of IGF-1R expressing cancer
|
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
|
ITUB20155272A1
(it)
|
2015-11-02 |
2017-05-02 |
Scuola Normale Superiore |
Intracellular antibody
|
|
WO2017079215A1
(en)
|
2015-11-03 |
2017-05-11 |
Glycomimetics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
|
EA201891093A1
(ru)
|
2015-11-03 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела, специфически связывающие pd-1, и их применение
|
|
ITUB20155097A1
(it)
|
2015-11-05 |
2017-05-05 |
Biouniversa Srl |
Anticorpi umanizzati anti-BAG3
|
|
US10829562B2
(en)
|
2015-12-10 |
2020-11-10 |
Katholieke Universiteit Leuven |
Haemorrhagic disorder due to ventricular assist device
|
|
KR20180087430A
(ko)
|
2015-12-17 |
2018-08-01 |
얀센 바이오테크 인코포레이티드 |
Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
|
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
|
KR20180093954A
(ko)
|
2015-12-23 |
2018-08-22 |
메디진 이뮤노테라피스 게엠바하 |
항원-특이적 tcr의 신규 생성
|
|
ES2861587T3
(es)
|
2015-12-31 |
2021-10-06 |
Progastrine Et Cancers S A R L |
Composiciones y métodos para detectar y tratar el cáncer de esófago
|
|
KR102477179B1
(ko)
|
2015-12-31 |
2022-12-13 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
위암의 검출 및 치료를 위한 조성물 및 방법
|
|
KR102428254B1
(ko)
|
2015-12-31 |
2022-08-03 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
난소암의 검출 및 치료를 위한 조성물 및 방법
|
|
EP3202788A1
(en)
|
2016-02-05 |
2017-08-09 |
MediaPharma S.r.l. |
Endosialin-binding antibody
|
|
WO2017140684A2
(en)
|
2016-02-15 |
2017-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
|
|
EP3205663A1
(en)
|
2016-02-15 |
2017-08-16 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for inhibiting gene expression
|
|
JP6966176B2
(ja)
|
2016-03-01 |
2021-11-10 |
イサム リサーチ ディベロップメント カンパニー オブ ザ ヘブルー ユニバーシティ オブ エルサレム エルティーディー． |
ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体
|
|
US11340233B2
(en)
|
2016-03-07 |
2022-05-24 |
Pierre Fabre Medicament |
Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
|
|
US11921116B2
(en)
|
2016-03-09 |
2024-03-05 |
Memorial Sloan Kettering Cancer Center |
Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
|
|
PL3779447T3
(pl)
|
2016-03-15 |
2023-06-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Sposób aktywowania przeciwnowotworowej odpowiedzi komórek t cd8+ u pacjenta dotknego nowotworem
|
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
|
EP3433615A1
(en)
|
2016-03-21 |
2019-01-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for diagnosis and treatment of solar lentigo
|
|
JP7080213B2
(ja)
|
2016-03-23 |
2022-06-03 |
スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド |
新規抗ｐｄ－ｌ１抗体
|
|
UA123785C2
(uk)
|
2016-03-28 |
2021-06-02 |
Інсайт Корпорейшн |
Сполуки піролотриазину як інгібітори tam
|
|
ITUA20162242A1
(it)
|
2016-04-01 |
2017-10-01 |
St Biochimico Italiano Giovanni Lorenzini Spa |
Un nuovo anticorpo anti-erbb2
|
|
HUE059732T2
(hu)
|
2016-04-18 |
2022-12-28 |
Faron Pharmaceuticals Oy |
Humanizált Clever-1 elleni antitestek és alkalmazásuk
|
|
WO2017191100A1
(en)
|
2016-05-03 |
2017-11-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of tissue lesions
|
|
CA3024027A1
(en)
|
2016-05-11 |
2017-11-16 |
Amgen Inc. |
Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
|
|
US20190290756A1
(en)
|
2016-05-20 |
2019-09-26 |
Christoph Karl |
Pharmaceutical compositions with anti-rankl antibodies, calcium and vitamin d
|
|
WO2017202814A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
|
|
EP3464357A1
(en)
|
2016-05-24 |
2019-04-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
|
|
KR20230042703A
(ko)
|
2016-06-07 |
2023-03-29 |
맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 |
Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포
|
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
|
DK3482210T3
(da)
|
2016-07-06 |
2021-07-12 |
Prothena Biosciences Ltd |
Assay til detektering af totalt og s129-phosphoryleret alpha-synuklein
|
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ |
新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
|
|
EP3487880A1
(en)
|
2016-07-25 |
2019-05-29 |
Biogen MA Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
|
EP3491387A1
(en)
|
2016-07-28 |
2019-06-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods of treatement of cancer disease by targetting tumor associated macrophage
|
|
KR102554331B1
(ko)
|
2016-08-12 |
2023-07-10 |
얀센 바이오테크 인코포레이티드 |
향상된 효능적 활성을 갖는 Fc 조작된 항-TNFR 수퍼패밀리 구성원 항체 및 그의 사용 방법
|
|
CA3033661A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
CA3034643A1
(en)
|
2016-09-20 |
2018-03-29 |
Ellen Weisberg |
Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
|
|
BR112019005247A2
(pt)
|
2016-10-07 |
2019-06-04 |
Daiichi Sankyo Co Ltd |
terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco
|
|
JPWO2018070390A1
(ja)
|
2016-10-12 |
2019-08-22 |
第一三共株式会社 |
抗ｒｏｂｏ４抗体と他剤を含む組成物
|
|
PE20191469A1
(es)
|
2016-10-13 |
2019-10-16 |
Massachusetts Inst Technology |
Anticuerpos que se unen a la proteina de envoltura el virus zika y usos de los mismos
|
|
IT201600111877A1
(it)
|
2016-11-07 |
2018-05-07 |
Biouniversa Srl |
Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
|
|
US10517966B2
(en)
|
2016-11-18 |
2019-12-31 |
Astellas Pharma Inc. |
Anti-human MUC1 antibody Fab fragment
|
|
US11273155B2
(en)
|
2016-12-12 |
2022-03-15 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
|
MX2019006897A
(es)
|
2016-12-13 |
2019-08-22 |
Astellas Pharma Inc |
Anticuerpo anti cd73 humana.
|
|
CA3047230A1
(en)
|
2016-12-15 |
2018-06-21 |
The National Institute for Biotechnology in the Negev Ltd. |
Anti-pcna monoclonal antibodies and use thereof
|
|
JP7202185B2
(ja)
|
2016-12-22 |
2023-01-11 |
第一三共株式会社 |
抗ｃｄ３抗体及び該抗体を含む分子
|
|
US20180179490A1
(en)
|
2016-12-27 |
2018-06-28 |
Miltenyi Biotec Gmbh |
CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
|
|
WO2018129284A1
(en)
|
2017-01-05 |
2018-07-12 |
The Johns Hopkins University |
Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma)
|
|
JP6679762B2
(ja)
|
2017-01-17 |
2020-04-15 |
第一三共株式会社 |
抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
|
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
|
BR112019016204A2
(pt)
|
2017-02-07 |
2020-07-07 |
Daiichi Sankyo Company, Limited |
anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d
|
|
EP3363459A1
(en)
|
2017-02-17 |
2018-08-22 |
Alexander Klimka |
Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis
|
|
CA3092434A1
(en)
|
2017-02-27 |
2018-08-30 |
Caerus Therapeutics, Inc. |
Compositions of a novel anti-human ceacam6 antibody and uses thereof
|
|
US20200061031A1
(en)
|
2017-02-28 |
2020-02-27 |
Kinki University |
Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
|
|
CN110753702B
(zh)
|
2017-03-15 |
2022-09-20 |
清华大学 |
抗trkb抗体
|
|
JOP20180021A1
(ar)
|
2017-03-16 |
2019-01-30 |
Janssen Biotech Inc |
الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
|
|
US11879014B2
(en)
|
2017-03-17 |
2024-01-23 |
Tusk Therapeutics Ltd. |
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
|
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
|
TWI782000B
(zh)
|
2017-03-30 |
2022-11-01 |
日商第一三共股份有限公司 |
抗ｇｐｒ２０抗體、其製造方法及其應用
|
|
KR102616819B1
(ko)
|
2017-03-30 |
2023-12-21 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
폐암을 치료하기 위한 조성물 및 방법
|
|
JP7071994B2
(ja)
|
2017-03-30 |
2022-05-19 |
プロガストリン、エ、カンセル、エス、アー エル、エル |
前立腺がんを治療するための組成物および方法
|
|
US10722589B2
(en)
|
2017-04-03 |
2020-07-28 |
Covagen Ag |
FGFR3 binding molecules
|
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
|
WO2018189335A1
(en)
|
2017-04-13 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
|
CN111201034A
(zh)
|
2017-05-11 |
2020-05-26 |
西托戴恩股份有限公司 |
涉及施用抗ccr5受体试剂的治疗或预防移植物抗宿主病的方法
|
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
|
|
MA52459A
(fr)
|
2017-06-05 |
2021-03-10 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation
|
|
WO2018226685A2
(en)
|
2017-06-06 |
2018-12-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
|
|
WO2019005503A1
(en)
|
2017-06-29 |
2019-01-03 |
Rutgers, The State University Of New Jersey |
COMPOSITIONS AND METHODS TARGETING G12 SIGNALING FOR BRONCHODILATORY THERAPY
|
|
WO2019004487A1
(ja)
|
2017-06-30 |
2019-01-03 |
国立大学法人北海道大学 |
成長障害を生じない小児骨粗鬆症治療薬
|
|
TWI795415B
(zh)
|
2017-07-07 |
2023-03-11 |
日商安斯泰來製藥股份有限公司 |
新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
|
|
BR112020001255A2
(pt)
|
2017-07-21 |
2020-07-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
composições imunogênicas de neisseria meningitidis
|
|
WO2019022187A1
(ja)
|
2017-07-27 |
2019-01-31 |
第一三共株式会社 |
抗ｃｄ１４７抗体
|
|
EP3658582A1
(en)
|
2017-07-28 |
2020-06-03 |
Intrepida Bio, Inc. |
Anti-bag3 antibodies as therapeutic reagent in cardiovascular diseases
|
|
EP3625254B1
(en)
|
2017-07-31 |
2023-12-13 |
F. Hoffmann-La Roche AG |
Three-dimensional structure-based humanization method
|
|
EP3444272A1
(en)
|
2017-08-17 |
2019-02-20 |
International-Drug-Development-Biotech |
Treatment of ck8 positive cancers in relation with k-ras gene status
|
|
MA49987A
(fr)
|
2017-08-23 |
2020-07-01 |
Daiichi Sankyo Co Ltd |
Préparation de conjugué anticorps-médicament et lyophilisation associée
|
|
AU2018321134A1
(en)
|
2017-08-23 |
2020-02-27 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Chimeric antigen receptor and CAR-T cells that bind CXCR5
|
|
CN111051330A
(zh)
|
2017-08-31 |
2020-04-21 |
第一三共株式会社 |
抗体-药物缀合物的改进制备方法
|
|
CN117838881A
(zh)
|
2017-08-31 |
2024-04-09 |
第一三共株式会社 |
制备抗体-药物缀合物的新方法
|
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
|
WO2019065964A1
(ja)
|
2017-09-29 |
2019-04-04 |
第一三共株式会社 |
抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
|
|
EP3692997A4
(en)
|
2017-10-03 |
2021-09-29 |
Tokyo Metropolitan Institute of Medical Science |
DRUG FOR INFLUENZA
|
|
CA3078436A1
(en)
|
2017-10-05 |
2019-04-11 |
Daiichi Sankyo Company, Limited |
Composition for cytotoxic t cell depletion
|
|
KR101966362B1
(ko)
*
|
2017-10-20 |
2019-04-05 |
주식회사 녹십자 |
항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
|
US11591385B2
(en)
|
2017-11-09 |
2023-02-28 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
|
BR112020010989A2
(pt)
|
2017-11-30 |
2020-11-17 |
Centurion Biopharma Corporation |
sistemas de distribuição de droga à base de maitansinoide
|
|
KR20200118408A
(ko)
|
2017-11-30 |
2020-10-15 |
센추리온 바이오파마 코포레이션 |
아우리스타틴 e 유도체의 알부민-결합 전구약물
|
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
|
JP7104153B2
(ja)
|
2017-12-05 |
2022-07-20 |
プロガストリン、エ、カンセル、エス、アー エル、エル |
癌を治療するための抗プロガストリン抗体と免疫療法の併用療法
|
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
|
US20190225689A1
(en)
|
2018-01-22 |
2019-07-25 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-pd-1 antibodies
|
|
TW201940881A
(zh)
|
2018-01-26 |
2019-10-16 |
瑞士商Ｅｃｓ前胃泌激素公司 |
在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
|
|
US11834487B2
(en)
|
2018-02-12 |
2023-12-05 |
Hadasit Medical Research Services & Development Ltd. |
Modulation of SLAMF6 splice variants for cancer therapy
|
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
|
IL303087B1
(en)
|
2018-02-27 |
2024-08-01 |
Incyte Corp |
Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors
|
|
CN112368579B
(zh)
|
2018-02-27 |
2024-05-03 |
Ecs前胃泌素股份有限公司 |
作为生物标记物的前胃泌素用于免疫疗法
|
|
SG11202008280TA
(en)
|
2018-03-05 |
2020-09-29 |
Univ Saitama Medical |
Pharmaceutical composition for treating or preventing heterotopic ossification
|
|
WO2019185683A1
(en)
|
2018-03-28 |
2019-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
US20210164984A1
(en)
|
2018-04-13 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
|
|
US12054529B2
(en)
|
2018-04-20 |
2024-08-06 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor and CAR-T cells that bind a herpes virus antigen
|
|
WO2019207066A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of sjögren's syndrome
|
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
AU2019264965A1
(en)
|
2018-05-09 |
2020-11-19 |
Nectin Therapeutics Ltd. |
Antibodies specific to human Nectin4
|
|
EP3795688A4
(en)
|
2018-05-11 |
2022-01-19 |
Astellas Pharma Inc. |
NUCLEIC ACID FOR THE TREATMENT OF ALLERGY TO MITES
|
|
AU2019268024A1
(en)
|
2018-05-11 |
2020-11-26 |
Astellas Pharma Inc. |
Nucleic acid for treating crustacean allergy
|
|
CA3100317A1
(en)
|
2018-05-17 |
2019-11-21 |
Astellas Pharma Inc. |
Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand
|
|
JP7391046B2
(ja)
|
2018-05-18 |
2023-12-04 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
|
|
JP7530299B2
(ja)
|
2018-05-24 |
2024-08-07 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ３抗体及びその使用
|
|
SG11202011268VA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Monospecific and multispecific anti-tmeff2 antibodies and there uses
|
|
PE20211916A1
(es)
|
2018-05-24 |
2021-09-28 |
Janssen Biotech Inc |
Agentes aglutinantes del psma y usos de estos
|
|
KR20210014660A
(ko)
|
2018-05-28 |
2021-02-09 |
다이이찌 산쿄 가부시키가이샤 |
항 her2 항체-약물 콘쥬게이트 투여에 의한 her2 변이암의 치료
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
BR112020021266A2
(pt)
|
2018-05-31 |
2021-01-26 |
Daiichi Sankyo Company, Limited |
anticorpo anti-tlr7 humano
|
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
CN112867394B
(zh)
|
2018-06-04 |
2024-09-13 |
马萨诸塞州渤健公司 |
具有降低的效应功能的抗vla-4抗体
|
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
|
JP2021527714A
(ja)
|
2018-06-20 |
2021-10-14 |
インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
抗ｐｄ−１抗体及びその使用
|
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
|
CN113164398B
(zh)
|
2018-06-29 |
2023-11-03 |
因赛特公司 |
Axl/mer抑制剂的制剂
|
|
WO2020007898A1
(en)
|
2018-07-04 |
2020-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating brain injury or neurodegenerative disease
|
|
UA128332C2
(uk)
|
2018-07-05 |
2024-06-12 |
Інсайт Корпорейшн |
Похідні конденсованих піразинів як інгібітори a2a/a2b
|
|
US20210283269A1
(en)
|
2018-07-25 |
2021-09-16 |
Daiichi Sankyo Company, Limited |
Effective method for manufacturing antibody-drug conjugate
|
|
US20210169852A1
(en)
|
2018-07-27 |
2021-06-10 |
Daiichi Sankyo Company, Limited |
Protein recognizing drug moiety of antibody-drug conjugate
|
|
JP7182308B2
(ja)
|
2018-07-27 |
2022-12-02 |
国立大学法人大阪大学 |
老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
|
|
AU2019315177A1
(en)
|
2018-07-31 |
2021-02-25 |
Daiichi Sankyo Company, Limited |
Treatment of metastatic brain tumor by administration of antibody-drug conjugate
|
|
CA3108754A1
(en)
|
2018-08-06 |
2020-02-13 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and tubulin inhibitor
|
|
US20220008549A1
(en)
|
2018-09-06 |
2022-01-13 |
Daiichi Sankyo Company, Limited |
Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
|
|
CN112912109A
(zh)
|
2018-09-20 |
2021-06-04 |
第一三共株式会社 |
通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症
|
|
US20230038521A1
(en)
|
2018-09-21 |
2023-02-09 |
National University Corporation Tokyo Medical An D Dental University |
Human Monoclonal Antibody Binding Specifically to Human Hmgb1, and Pharmaceutical Composition for Treating or Preventing Alzheimer's Disease Containing Said Human Monoclonal Antibody
|
|
AU2019350536A1
(en)
|
2018-09-27 |
2021-05-06 |
Pierre Fabre Medicament |
Sulfomaleimide-based linkers and corresponding conjugates
|
|
CA3114179A1
(en)
|
2018-09-28 |
2020-04-02 |
Pierre Fabre Medicament |
New immunocytokines for the treatment of cancer
|
|
MX2021004146A
(es)
|
2018-10-10 |
2021-06-08 |
Astellas Pharma Inc |
Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
JP2022505113A
(ja)
|
2018-10-18 |
2022-01-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
固形腫瘍の処置のためのβｉｇ－ｈ３アンタゴニストと免疫チェックポイント阻害剤との組み合わせ
|
|
KR20210084473A
(ko)
|
2018-10-31 |
2021-07-07 |
아스텔라스세이야쿠 가부시키가이샤 |
항인간 Fn14 항체
|
|
WO2020099235A1
(en)
|
2018-11-12 |
2020-05-22 |
Mediapharma S.R.L. |
Bispecific antibodies directed against human 90k and either endosialin or her3
|
|
KR20210091711A
(ko)
|
2018-11-14 |
2021-07-22 |
다이이찌 산쿄 가부시키가이샤 |
항 cdh6 항체-피롤로벤조디아제핀 유도체 컨쥬게이트
|
|
US20220023436A1
(en)
|
2018-12-11 |
2022-01-27 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with parp inhibitor
|
|
EP3903828A4
(en)
|
2018-12-21 |
2022-10-05 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
|
|
NL2024544B1
(en)
|
2018-12-21 |
2021-03-15 |
Aim Immunotech Inc |
Compositions And Methods For Cancer Therapy
|
|
JOP20210183A1
(ar)
|
2019-01-07 |
2023-01-30 |
Astellas Pharma Inc |
مادة اقتران تشتمل على ربيطة وشدفة Fab لجسم مضاد لـ CEACAM5
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
AU2020207664A1
(en)
|
2019-01-13 |
2021-07-22 |
University Of Rijeka Faculty Of Medicine |
Antibodies specific to human Nectin-2
|
|
US20220125754A1
(en)
|
2019-01-29 |
2022-04-28 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Treating the causative agent in adhesiogenesis
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
MX2021009662A
(es)
|
2019-02-13 |
2021-09-08 |
Brigham & Womens Hospital Inc |
Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.
|
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
|
KR20210152472A
(ko)
|
2019-03-11 |
2021-12-15 |
메모리얼 슬로안 케터링 캔서 센터 |
Cd22 항체 및 이를 사용하는 방법
|
|
EP3942026A1
(en)
|
2019-03-22 |
2022-01-26 |
Université de Paris |
New inhibitors of lrrk2/pp1 interaction
|
|
CN113631184A
(zh)
|
2019-03-25 |
2021-11-09 |
马克思-德布鲁克-分子医学中心亥姆霍兹联合会 |
通过抑制ebag9增强溶细胞性t细胞活性
|
|
US20220168440A1
(en)
|
2019-03-25 |
2022-06-02 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine deprivative conjugate
|
|
AU2020246448A1
(en)
|
2019-03-25 |
2021-10-14 |
Daiichi Sankyo Company, Limited |
Anti-HER2 antibody-pyrrolobenzodiazepine derivative conjugate
|
|
JP7522097B2
(ja)
|
2019-03-27 |
2024-07-24 |
第一三共株式会社 |
抗体－ピロロベンゾジアゼピン誘導体コンジュゲートとｐａｒｐ阻害剤の組み合わせ
|
|
US20220193064A1
(en)
|
2019-04-01 |
2022-06-23 |
Chiome Bioscience Inc. |
Medicament for treating cancer
|
|
EP3946626A1
(en)
|
2019-04-02 |
2022-02-09 |
Kenjockety Biotechnology, Inc. |
Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
|
US11591395B2
(en)
|
2019-04-19 |
2023-02-28 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
|
|
EP3962529A4
(en)
|
2019-04-30 |
2023-11-01 |
Dana-Farber Cancer Institute, Inc. |
METHOD FOR CANCER TREATMENT USING ANTI-CX3CR1 AND IMMUNE CHECKPOINT BLOCKING REAGENTS COMBINATIONS
|
|
CN114007642A
(zh)
|
2019-04-30 |
2022-02-01 |
森迪生物科学公司 |
嵌合受体及其使用方法
|
|
EP3969569A1
(en)
|
2019-05-14 |
2022-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
|
|
AU2020285681A1
(en)
|
2019-05-29 |
2022-01-27 |
Daiichi Sankyo Company, Limited |
Dosage of an antibody-drug conjugate
|
|
CN114286828A
(zh)
|
2019-06-24 |
2022-04-05 |
诺华股份有限公司 |
针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
|
|
US12077585B2
(en)
|
2019-07-26 |
2024-09-03 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
|
US20220267453A1
(en)
|
2019-07-26 |
2022-08-25 |
Saitama Medical University |
Antibody recognizing extracellular region of alk2/acvr1
|
|
WO2021019706A1
(ja)
|
2019-07-31 |
2021-02-04 |
国立大学法人信州大学 |
Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
|
|
JP2022543062A
(ja)
|
2019-08-01 |
2022-10-07 |
インサイト・コーポレイション |
Ｉｄｏ阻害剤の投与レジメン
|
|
EP4007603A1
(en)
|
2019-08-02 |
2022-06-08 |
CytoDyn Inc. |
Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
|
|
JP7284256B2
(ja)
|
2019-08-12 |
2023-05-30 |
ビオンド バイオロジクス リミテッド |
Ｉｌｔ２に対する抗体およびその使用
|
|
EP3792632A1
(en)
|
2019-09-16 |
2021-03-17 |
Vito NV |
Immunotherapy markers
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
EP4034151A1
(en)
|
2019-09-27 |
2022-08-03 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
|
JP2022550067A
(ja)
|
2019-09-27 |
2022-11-30 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｅａｃａｍ抗体及びその使用
|
|
JPWO2021079958A1
(nl)
|
2019-10-25 |
2021-04-29 |
|
|
|
MX2022005904A
(es)
|
2019-11-15 |
2022-09-07 |
Pliant Therapeutics Inc |
Composiciones y metodos para la activacion de integrinas.
|
|
IL293051A
(en)
|
2019-11-18 |
2022-07-01 |
Janssen Biotech Inc |
calr and jak2 mutant-based vaccines and their uses
|
|
US11396541B2
(en)
|
2019-12-20 |
2022-07-26 |
Novarock Biotherapeutics, Ltd. |
Anti-interleukin-23 P19 antibodies and methods of use thereof
|
|
KR20220150281A
(ko)
|
2020-01-03 |
2022-11-10 |
인사이트 코포레이션 |
A2a/a2b 및 pd-1/pd-l1 억제제를 포함하는 조합 요법
|
|
WO2021140173A1
(en)
|
2020-01-10 |
2021-07-15 |
Biouniversa S.R.L. |
Methods and uses for treating fibrotic solid tumors with bags inhibitors
|
|
EP4100525A1
(en)
|
2020-02-05 |
2022-12-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods of treatment of cancer disease by targeting an epigenetic factor
|
|
TW202140012A
(zh)
|
2020-02-12 |
2021-11-01 |
比利時商健生藥品公司 |
用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
EP4114368A1
(en)
|
2020-03-03 |
2023-01-11 |
Active Biotech AB |
Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
|
|
IL296124A
(en)
|
2020-03-06 |
2022-11-01 |
Daiichi Sankyo Co Ltd |
Conjugation of an antibody with a drug including a novel cyclic dinucleotide derivative
|
|
CN115697343A
(zh)
|
2020-03-06 |
2023-02-03 |
因赛特公司 |
包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
|
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
UY39130A
(es)
|
2020-03-13 |
2021-09-30 |
Janssen Biotech Inc |
Materiales y métodos para la unión de lectina tipo ig de unión a ácido siálico
|
|
EP4130036A4
(en)
|
2020-03-30 |
2024-05-15 |
National Cancer Center |
ANTIBODY-DRUG CONJUGATE
|
|
US11045546B1
(en)
|
2020-03-30 |
2021-06-29 |
Cytodyn Inc. |
Methods of treating coronavirus infection
|
|
EP3889183A1
(en)
|
2020-04-01 |
2021-10-06 |
Pierre Fabre Medicament |
A protein complex comprising an immunocytokine
|
|
WO2021205438A1
(en)
|
2020-04-06 |
2021-10-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
|
|
TW202144429A
(zh)
|
2020-05-14 |
2021-12-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途
|
|
WO2021233962A1
(en)
|
2020-05-19 |
2021-11-25 |
Institut Curie |
Methods for the diagnosis and treatment of cytokine release syndrome
|
|
KR20230017841A
(ko)
|
2020-05-27 |
2023-02-06 |
얀센 바이오테크 인코포레이티드 |
Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
|
|
EP4159859A4
(en)
|
2020-05-27 |
2024-07-10 |
Arialys Therapeutics Inc |
ANTI-HUMAN NR1 ANTIBODY DERIVATIVE
|
|
CN116529267A
(zh)
|
2020-06-04 |
2023-08-01 |
肯乔克蒂生物技术股份有限公司 |
Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
|
|
KR20230043109A
(ko)
|
2020-06-24 |
2023-03-30 |
아스트라제네카 유케이 리미티드 |
항체-약물 접합체 및 atr 억제제의 조합
|
|
WO2021260583A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and dna-pk inhibitor
|
|
EP4171654A1
(en)
|
2020-06-24 |
2023-05-03 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and cdk9 inhibitor
|
|
WO2021260582A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and aurora b inhibitor
|
|
JP2023539715A
(ja)
|
2020-06-24 |
2023-09-19 |
アストラゼネカ ユーケー リミテッド |
抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
|
|
US20230305023A1
(en)
|
2020-06-25 |
2023-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment and diagnostic of pathological conditions associated with intense stress
|
|
US20230277679A1
(en)
|
2020-07-17 |
2023-09-07 |
Daiichi Sankyo Company, Limited |
Method for producing antibody-drug conjugate
|
|
AU2021312537A1
(en)
|
2020-07-20 |
2023-03-09 |
Daiichi Sankyo Company, Limited |
Combination of (anti-HER2 antibody)-drug conjugate and her dimerization inhibitor
|
|
WO2022024024A2
(en)
|
2020-07-29 |
2022-02-03 |
Janssen Biotech, Inc. |
Proteins comprising hla-g antigen binding domains and their uses
|
|
RU2764216C1
(ru)
*
|
2020-08-10 |
2022-01-14 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" |
Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
|
|
TW202221035A
(zh)
|
2020-08-12 |
2022-06-01 |
以色列商拜恩德生物製品有限公司 |
抗ilt2抗體及其用途
|
|
EP4199959A1
(en)
|
2020-08-24 |
2023-06-28 |
Charité - Universitätsmedizin Berlin |
A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing cd44v6
|
|
EP4199958A1
(en)
|
2020-08-24 |
2023-06-28 |
Charité - Universitätsmedizin Berlin |
Chimeric antigen receptor (car)-expressing cells recognizing cea
|
|
CA3193584A1
(en)
|
2020-09-04 |
2022-03-10 |
Novarock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
|
WO2022049273A1
(en)
|
2020-09-07 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of inflammatory bowel diseases
|
|
CA3195062A1
(en)
|
2020-09-12 |
2022-03-17 |
Astrazeneca Uk Limited |
A scoring method for an anti-her2 antibody-drug conjugate therapy
|
|
CA3198077A1
(en)
|
2020-10-05 |
2022-04-14 |
Chiome Bioscience Inc. |
Medicine for treating cancer
|
|
AU2021356762A1
(en)
|
2020-10-09 |
2023-05-25 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
|
KR20230086765A
(ko)
|
2020-10-13 |
2023-06-15 |
얀센 바이오테크 인코포레이티드 |
분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
|
|
WO2022084399A1
(en)
|
2020-10-21 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
C-terminal sparc fragments for treating cancer
|
|
US20240025992A1
(en)
|
2020-10-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
|
|
WO2022097090A1
(en)
|
2020-11-05 |
2022-05-12 |
Novartis Ag |
Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
|
|
EP4240874A1
(en)
|
2020-11-06 |
2023-09-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for diagnosis and treating polycystic ovary syndrome (pcos)
|
|
US20230414778A1
(en)
|
2020-11-11 |
2023-12-28 |
Daiichi Sankyo Company, Limited |
COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
|
|
WO2022102695A1
(ja)
|
2020-11-12 |
2022-05-19 |
第一三共株式会社 |
抗ｂ７－ｈ３抗体－薬物コンジュゲート投与による中皮腫の治療
|
|
AR124063A1
(es)
|
2020-11-16 |
2023-02-08 |
Astellas Pharma Inc |
Anticuerpo biespecífico anti-tspan8 / anti-cd3 y anticuerpo anti-tspan8
|
|
WO2022112469A1
(en)
|
2020-11-27 |
2022-06-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring of toxic epidermal necrolysis
|
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
|
US20220241411A1
(en)
|
2020-11-30 |
2022-08-04 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
|
WO2022124247A1
(ja)
|
2020-12-09 |
2022-06-16 |
国立大学法人 東京医科歯科大学 |
前頭側頭葉変性症の予防又は治療剤
|
|
CN117500503A
(zh)
|
2020-12-29 |
2024-02-02 |
因赛特公司 |
包含a2a/a2b抑制剂、pd-1/pd-l1抑制剂和抗cd73抗体的组合疗法
|
|
KR20230146521A
(ko)
|
2021-01-13 |
2023-10-19 |
메모리얼 슬로안 케터링 캔서 센터 |
항체-피롤로벤조디아제핀 유도체 접합체
|
|
WO2022153212A1
(en)
|
2021-01-13 |
2022-07-21 |
Axon Neuroscience Se |
Antibodies neutralizing sars-cov-2
|
|
AU2022208361A1
(en)
|
2021-01-13 |
2023-07-27 |
Daiichi Sankyo Company, Limited |
Anti-dll3 antibody-drug conjugate
|
|
PE20240761A1
(es)
|
2021-01-28 |
2024-04-17 |
Janssen Biotech Inc |
Proteinas de union a psma y usos de estas
|
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體－免疫賦活化劑共軛物之新穎製造方法
|
|
AU2022219681A1
(en)
|
2021-02-11 |
2023-09-21 |
Nectin Therapeutics Ltd. |
Antibodies against cd112r and uses thereof
|
|
EP4291577A1
(en)
|
2021-02-12 |
2023-12-20 |
Boehringer Ingelheim International GmbH |
Complement c3 antigen binding proteins
|
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
|
MX2023010238A
(es)
|
2021-03-02 |
2023-12-05 |
Dana Farber Cancer Inst Inc |
Métodos para tratar trastornos de glóbulos rojos.
|
|
JPWO2022191313A1
(nl)
|
2021-03-12 |
2022-09-15 |
|
|
|
WO2022189632A1
(en)
|
2021-03-12 |
2022-09-15 |
Fibrosys S.R.L. |
Monoclonal antibodies for the treatment of viral infections
|
|
CA3214307A1
(en)
|
2021-03-24 |
2022-09-29 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
|
TW202304986A
(zh)
|
2021-03-24 |
2023-02-01 |
美商健生生物科技公司 |
靶向cd22及cd79b的抗體
|
|
EP4314059A1
(en)
|
2021-03-26 |
2024-02-07 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
|
WO2022218998A1
(en)
|
2021-04-13 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating hepatitis b and d virus infection
|
|
WO2022221409A1
(en)
|
2021-04-14 |
2022-10-20 |
Villaris Therapeutics, Inc. |
Anti-cd122 antibodies and uses thereof
|
|
IL307744A
(en)
|
2021-04-22 |
2023-12-01 |
Astellas Pharma Inc |
Anti-CLDN4/anti-CD137 bispecific antibody
|
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
|
CN113361141B
(zh)
*
|
2021-07-11 |
2022-02-18 |
西南石油大学 |
一种dna图谱算法的改进试验方法
|
|
WO2023026235A1
(en)
|
2021-08-27 |
2023-03-02 |
Janssen Biotech, Inc. |
Anti-psma antibodies and uses thereof
|
|
CN118317795A
(zh)
|
2021-09-15 |
2024-07-09 |
第一三共株式会社 |
用在治疗化疗耐药性癌症的方法中的抗体-药物偶联物
|
|
EP4401715A1
(en)
|
2021-09-17 |
2024-07-24 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
EP4405392A1
(en)
|
2021-09-24 |
2024-07-31 |
Janssen Biotech, Inc. |
Proteins comprising cd20 binding domains, and uses thereof
|
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
|
KR20240099178A
(ko)
|
2021-10-18 |
2024-06-28 |
다이이찌 산쿄 가부시키가이샤 |
항 cd37 항체-약물 콘주게이트
|
|
WO2023073084A1
(en)
|
2021-10-27 |
2023-05-04 |
Imcheck Therapeutics |
Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
|
|
EP4177266A1
(en)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
|
CA3238116A1
(en)
|
2021-11-18 |
2023-05-25 |
Matthew Simon SUNG |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
|
EP4433089A1
(en)
|
2021-11-19 |
2024-09-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
|
JP7235262B1
(ja)
|
2021-12-07 |
2023-03-08 |
国立大学法人大阪大学 |
抗体又はその抗原結合性断片
|
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
|
KR20240131370A
(ko)
|
2021-12-22 |
2024-08-30 |
인사이트 코포레이션 |
항-cd19 항체 요법을 위한 치료 패러다임
|
|
WO2023126823A1
(en)
|
2021-12-28 |
2023-07-06 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and atr inhibitor
|
|
EP4456899A1
(en)
|
2021-12-28 |
2024-11-06 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and rasg12c inhibitor
|
|
CN118591554A
(zh)
|
2022-01-27 |
2024-09-03 |
凯奥目生物科学株式会社 |
抗人cxcl1抗体
|
|
WO2023152581A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Method of treating cancer with psmaxcd3 antibody
|
|
AU2023229142A1
(en)
|
2022-03-02 |
2024-10-03 |
Daiichi Sankyo Company, Limited |
METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
|
|
WO2023166081A1
(en)
|
2022-03-02 |
2023-09-07 |
Heidelberg Immunotherapeutics Gmbh |
Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
|
|
WO2023171009A1
(ja)
|
2022-03-09 |
2023-09-14 |
株式会社Cured |
Ｅｖａ１タンパク質に結合する、ヒト化抗体又はその機能的断片、抗体薬物複合体及びキメラ抗原受容体
|
|
AU2023235594A1
(en)
|
2022-03-15 |
2024-09-12 |
Yeda Research And Development Co. Ltd. |
Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
|
|
CN118891525A
(zh)
|
2022-03-16 |
2024-11-01 |
阿斯利康(英国)有限公司 |
用于抗trop2抗体-药物缀合物疗法的评分方法
|
|
WO2023209591A1
(en)
|
2022-04-27 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
|
WO2023218378A1
(en)
|
2022-05-11 |
2023-11-16 |
Daiichi Sankyo Company, Limited |
Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
|
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
|
TW202412859A
(zh)
|
2022-07-28 |
2024-04-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及雙特異性檢查點抑制劑之組合
|
|
WO2024072893A1
(en)
|
2022-09-28 |
2024-04-04 |
Incyte Corporation |
Anti-pd-1/lag-3 bispecific antibodies and uses thereof
|
|
WO2024074498A1
(en)
|
2022-10-04 |
2024-04-11 |
Imcheck Therapeutics |
Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
|
|
WO2024116094A1
(en)
|
2022-11-30 |
2024-06-06 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugates and dnmt inhibitors
|
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|
|
WO2024127366A1
(en)
|
2022-12-16 |
2024-06-20 |
Pheon Therapeutics Ltd |
Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
|
|
WO2024170505A1
(en)
|
2023-02-13 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of iron overload associated diseases
|
|
WO2024175699A1
(en)
|
2023-02-23 |
2024-08-29 |
Imcheck Therapeutics |
Combination of btn3a activating antibody and immune checkpoint inhibitors
|
|
WO2024184476A1
(en)
|
2023-03-07 |
2024-09-12 |
Institut Curie |
Ung/udg inhibition in brca-associated cancer
|
|
WO2024194401A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Vps4b inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194402A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194673A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Methods for the treatment of dedifferentiated liposarcoma
|
|
WO2024213782A1
(en)
|
2023-04-13 |
2024-10-17 |
Institut Curie |
Methods for the treatment of t-cell acute lymphoblastic leukemia
|
|
WO2024215978A1
(en)
|
2023-04-14 |
2024-10-17 |
Incyte Corporation |
Use of an anti-tgfbetar2/pd-1 bispecific antibody to treat cancer
|
|
WO2024223943A1
(en)
|
2023-04-27 |
2024-10-31 |
Imcheck Therapeutics |
Methods for treating multidrug resistant bacterial infections
|